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It is well recognized that the tumor microenvironment plays a key role in cancer 
initiation, progression, and response to treatment. Therapies targeted towards the tumor 
microenvironment are being introduced in the clinic to be administered alongside 
chemotherapy and radiation, however, not every patient responds to treatment. The 
purpose of this dissertation is to characterize modulation of the tumor microenvironment 
induced by targeted therapies, and build a better understanding of how to exploit these 
alterations to increase efficacy of developing combination treatments. Our objective is 
addressed in three parts. First, we quantified temporal alterations in nuclear factor kappa 
B signaling and downstream gene expression to a small-molecule pathway inhibitor and 
demonstrated the complexity of altering pathway dynamics for therapeutic gain. 
Secondly, we characterized changes in innate immune cell infiltration in human 
epidermal growth factor receptor 2 positive (HER2+) breast cancer after targeted 
antibody treatment and identified mechanisms of vascular alterations and windows of 
reduced immune suppression. Lastly, we quantified the effects of radiation and targeted 
 vii 
antibody therapy in HER2+ breast cancer and elucidated a potential to reduce radiation 
dose in this combination regimen. Collectively, the results presented provide valuable 
insight of how the tumor microenvironment can dictate treatment response and the 
potential to modulate the tumor microenvironment to enhance therapeutic efficacy. 
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Chapter 1: Introduction 
1.1 MOTIVATION 
In 2000, Hanahan and Weinberg identified six characteristics that defined a cell as 
cancerous. The underlying focus of these characteristics was that cancer is a genetic 
disease and the instability of the genome of the cancer cell leads to tumor progression [1].  
In addition to genomic instability, scientists now recognize that the tumor 
microenvironment plays a critical role in cancer initiation,  progression, and response to 
treatment [2–4]. Three crucial aspects of the tumor microenvironment modulating 
tumorigenesis are molecular cytokines that activate survival signaling networks, chronic 
angiogenesis, and tumor promoting inflammation [2].   
Growth factors promoting cell proliferation are produced in normal tissues to 
maintain homeostasis and ensure proper cell turnover. Cancer cells can develop the 
ability to sustain proliferative signaling by deregulating signaling pathways and resisting 
apoptosis [5]. Tumors also promote chronic angiogenesis, a process largely quiescent in 
normal tissues. The development of new vasculature provides nutrients necessary for 
tumor growth. Additionally, much of this vasculature is irregular leading to areas of 
hypoxia which reduces tumor response to treatment [6, 7]. Thirdly, inflammation by 
innate immune cells can promote tumor escape by secreting cytokines that increase 
cancer cell proliferation and angiogenesis. Inflammatory cells also have the ability to 
suppress adaptive immune responses and assist in cancer immune evasion [8–10].  
Efforts to combat tumor promoting factors in the microenvironment include small 
molecule pathway inhibitors to inhibit cancer cell proliferative signaling,  anti-angiogenic 
therapies to reduce tumor angiogenesis, and immunotherapies aimed to strengthen a 
patient’s immune system to attack cancer cells and evade immunosuppression [11–15].  
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While an increasing number of therapies targeting the tumor microenvironment 
are being introduced in the clinic, not every patient responds to such treatment. There 
have been recent efforts to better understand the tumor microenvironment and manipulate 
it to decrease metastatic potential and favor tumor regression [3, 16]. The overall goal of 
this dissertation is to quantify treatment-induced temporal changes of the tumor 
microenvironment to provide insight for optimizing clinical combination treatment 
regimens in cancer. We accomplished this goal in the three areas described below. 
1.2 OBJECTIVES 
1.2.1 Aim 1: Quantify temporal changes in NF-κB signaling and downstream gene 
expression 
Small molecule approaches targeting the nuclear factor kappa B (NF-kB) 
pathway, a regulator of inflammation, have thus far proven unsuccessful in the clinic in 
part due to the complex pleiotropic nature of this network [17–19]. Downstream effects 
depend on multiple factors including stimulus-specific temporal patterns of NF-kB 
activity [17, 20]. Despite considerable advances, genome-level impact of changes in 
temporal NF-kB activity caused by inhibitors and their stimulus dependency remains 
unexplored. Temporal nuclear translocation of NF-κB was quantified from 
immunofluorescent images of 3T3 fibroblasts stimulated with interleukin 1 beta (IL-1β) 
and tumor necrosis factor alpha (TNF-α) when treated with 10-100 μM of SC-514 
(inhibitor kappa B subunit beta (IKKβ) inhibitor, IC50 3-12 μM). Inflammatory genes of 
interest were evaluated for differences in gene expression between experimental 
conditions through RNA TagSeq. In this section, the effects of selective perturbation on 
NF-κB transcriptional dynamics applicable for developing NF-κB pathway targeted drugs 
were evaluated. 
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1.2.2 Aim 2: Identify temporal changes in myeloid cell infiltration in HER2+ breast 
cancer  
Therapy targeted to the human epidermal growth factor receptor 2 (HER2) is used 
in combination with cytotoxic therapy in the clinical treatment of HER2+ breast cancer. 
Trastuzumab, an anti-HER2 therapy, has been shown to induce vascular changes that can 
increase delivery of chemotherapy [21, 22]. To quantify the role of immune modulation 
in treatment-induced vascular changes, this aim identifies temporal changes in myeloid 
cell infiltration with corresponding vascular alterations in a preclinical model of HER2+ 
breast cancer following trastuzumab therapy. Alterations in myeloid cell types were 
evaluated by immunophenotyping using flow cytometry. Immunohistochemistry staining 
validated tumor vascular alterations coinciding with immune alterations. Additionally, 
inflammatory cytokine and chemokine differences were evaluated between control and 
treated tumors to elucidate mechanisms of immune response. This section reveals 
mechanistic properties of improved tumor vascularization and potential windows of 
reduced immune suppression in trastuzumab treated HER2+ breast cancer tumors.  
1.2.3 Aim 3: Quantify the effects of combination trastuzumab and radiation therapy 
longitudinally in HER2+ breast cancer 
Radiation is used in combination with trastuzumab as an adjuvant therapy to 
eliminate residual cancer cells that may be remaining in the breast tissue or chest wall 
[23, 24]. The use of adjuvant radiation reduces the risk of cancer returning, however; 
patients with HER2+ breast cancer are more likely to have a recurrence than HER2- 
patients [25, 26]. Studies show HER2 signaling can modulate resistance to radiation 
treatment, and trastuzumab may act as a radiosensitizer [27–31]. To determine if 
trastuzumab sensitizes breast cancer cells to radiation, treatment effects were quantified 
in BT474, SKBR3, and MDA-MB-231 cell lines using measurements of cell proliferation 
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through in vitro time-resolved microscopy. Furthermore, this aim shows tumor response 
to combination treatment in an in vivo mouse model of HER2+ breast cancer and reveals 
potential tumor microenvironmental alterations affecting tumor response.  
1.3 ORGANIZATION 
The remainder of this dissertation is organized as follows. In Chapter 2, the 
background necessary to understand the clinical significance of this work is discussed. 
Chapter 3 quantifies stimulus specific responses of NF-κB signal dynamics to targeted 
small molecule therapy and alterations in gene expression. This chapter demonstrates 
small molecule inhibitors acting on pathway components can alter signal dynamics in a 
stimulus-dependent manner and affect gene response in complex ways.  Chapter 4 shows 
innate immune alterations in HER2+ breast cancer tumors after treatment with anti-HER2 
therapy. This chapter shows correlations between immune modulation and vascular 
changes in HER2+ breast cancer and the potential for anti-HER2 therapy to modulate 
immunosuppressive components of the tumor microenvironment. Chapter 5 shows in 
vitro combination trastuzumab and radiation effects are additive, however, in vivo 
combination treatment enhances the rate of tumor regression. This chapter shows the 
potential of using a lesser dose of radiation when administering trastuzumab in a 
combination regimen. Chapters 3-5 each contain the respective study’s motivations, 
methods, results and limitations. Finally, Chapter 6 summarizes the impact of this work 
and future directions. 
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Chapter 2:  Background  
2.1 NF-ΚB 
2.1.1 NF-κB Signaling Pathway 
Nuclear factor kappa B (NF-κB) is an inducible transcription factor represented 
by a family of five proteins—RelA (p65), RelB, c-Rel, NF-κB1 (p105/50) and NF-κB2 
(p100/52). These five proteins form homo- and heterodimers that play a role in the 
regulation of multiple biological processes including cell proliferation, differentiation and 
survival [32]. The p50:p65 heterodimer is the most prevalent NF-κB dimer among cell 
types and widely studied in the context of pathway function and regulation in disease 
[32–35]. Activation of NF-κB occurs through two separate signaling pathways, canonical 
(classical) and non-canonical (alternative) [36]; however, recent studies provide evidence 
of cross-talk between the two [37, 38]. The non-canonical pathway is activated through 
the engagement of a small subset of tumor necrosis factor receptors and plays a role in 
lymphoid organogenesis and B cell maturation and survival [39]. The canonical NF-κB 
signaling pathway has been studied in greater detail and is activated through engagement 
of numerous cytokine receptors, tumor necrosis factor receptors, pattern-recognition 
receptors and the B and T cell receptor [32, 39]. Misregulation of both the canonical and 
non-canonical NF-κB pathways play a role in cancer progression [18, 34, 40]. 
NF-κB is held inactive in cells through inhibitor kappa B proteins (IκBs). Upon 
activation, a series of phosphorylation events occur, releasing NF-κB to the nucleus 
where gene transcription takes place [36]. An essential regulator of NF-κB nuclear 
translocation is the inhibitory IκB kinase (IKK) complex which consists of three subunits, 
IKKα, IKKβ and IKKγ [36, 41]. The IKK complex is responsible for the phosphorylation 
of the specific inhibitory protein sequestering NF-κB in the cytoplasm, IκBα [41]. In the 
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nucleus, NF-κB drives the expression of IκBα, creating one mechanism of negative 
feedback [42, 43]. A diverse range of stimuli activate IKK including inflammatory 
cytokines, growth factors, microbial pathogens and cellular stress [44]. Many of the 
stimuli that activate NF-κB are present in the tumor microenvironment including tumor 
necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) [45, 46]. 
2.1.2 NF-κB in Cancer 
With NF-kB being a key modulator in cell survival and inflammation, loss of 
proper regulation can directly contribute to several of the hallmarks of cancer described 
by Hanahan and Weinberg including sustaining proliferative signaling, tumor-promoting 
inflammation, and avoiding immune destruction [1, 34, 47]. Regulatory feedback 
mechanisms are crucial for proper NF-κB control and maintaining biological 
homeostasis. In cancer cells, NF-κB can become constitutively activated and promote 
tumorigenesis. In human breast cancer specimens, activated NF-kB was found in over 
80% of HER2+ samples [48]. In a preclinical human xenograft model of colorectal 
cancer, Sakamoto et al. found evidence of constitutive NF-κB activation in 40% of tissue 
samples [49]. Loss of negative feedback has been shown to occur through genetic 
mutations in the NF- κB pathway. For example, Bredel et al. found deletions of at least 
one copy of the inhibitor protein IκBα in 24.2% of glioblastoma patient samples (N = 
219) [50]. Several studies show frequent mutations in IκBα in malignant cells in 
Hodgkin’s lymphoma, where upregulation of NF- κB is consistently observed [51–53].  
Chronic NF-κB activation promotes cell proliferation and prevents apoptosis, 
driving cancer cells towards metastasis. For example, NF-κB upregulation has been 
linked with increased cell proliferation and metastatic potential in hormone receptor 
negative (estrogen and progesterone) cell lines [54, 55]. NF- κB encodes for many genes 
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that suppress apoptotic responses including the inhibitor of apoptosis (IAP) protein, c-
IAP2 [56]. c-IAP2 prevents apoptosis induced by effector caspases [57]. Furthermore, 
NF-κB activity in cancer cells can lead to chemotherapy and radiation resistance, partly 
through the encoding of the multidrug resistance protein 1 [58–60].  
2.1.3 NF-κB as a Therapeutic Target 
NF-κB has been explored as a therapeutic target in cancer for many years [61–
63]. Inhibiting NF-κB activation in cancer cells to enhance tumor regression in 
preclinical studies shows promising results. Two preclinical mouse models of breast 
cancer treated with an NF-κB inhibitor had greater decrease in tumor size over two 
months than control tumors [64]. There is also evidence targeting NF- κB could improve 
therapeutic response to chemotherapy. In vitro, NF-κB inhibition enhanced the 
cytotoxicity of doxorubicin by increasing apoptosis of osteosarcoma cancer cell [65]. 
However, no therapies directly targeted to the NF-κB pathway have successfully made it 
to the clinic.  
NF-κB activation is not only present in cancer cells but also in innate and adaptive 
immune cells present in the tumor microenvironment. Although NF-κB promotes tumor 
escape when activated in cancer cells, it can promote anti-tumor immunity by stimulating 
T cell activation [66, 67].  In a preclinical mouse model, impairment of NF-κB activation 
led to decrease in CD8+ (cytotoxic) T cell response to pathogens [68]. Another study 
showed mice with inhibited NF-κB signaling downstream of the T cell receptor (murine 
fibrosarcoma) were unable to reject tumors compared to mice with functioning NF-κB 
signaling pathways [40]. On the contrary, NF-κB activation has been shown to promote 
macrophage polarization towards an immunosuppressive phenotype and inhibiting NF-
κB pathway function in macrophages promotes tumor regression [69, 70].  NF-κB can 
 8 
have conflicting roles in cancer progression depending on the cell of interest, therefore 
defining a target cell phenotype is an important consideration when developing NF-κB 
pathway inhibitors.  
2.2 HER2+ BREAST CANCER 
2.2.1 HER2 
Human epidermal growth factor receptor 2 positive (HER2+) breast cancer is 
characterized by overexpression of the HER2/neu receptor [71]. HER2 is a 
transmembrane receptor tyrosine kinase that normally is expressed on epithelial cells in 
the breast, but when overexpressed in breast cancer cells, HER2 drives proliferation and 
survival [72, 73]. HER2 is part of the epidermal growth factor receptor family which 
includes three other HER receptors (HER1, HER3, and HER4). HER2 signaling is 
activated through dimerization with one of the other ligand bound HER family members. 
Upon dimerization, pro-survival signaling pathways are activated including 
phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin 
(PI3K/Akt/mTOR) and Ras/Raf/mitogen-activated protein kinase (MAPK) pathways [74, 
75]. HER2 overexpression appears in 15-20% of breast cancer cases [71]. Patients with 
HER2+ status have a three times higher risk of recurrence and five times higher risk of 
metastasis than HER2- patients [26, 76]. Metastasis to the brain, a particularly difficult 
site to treat, is also more likely in HER2+ patients [77, 78]. Furthermore, less than half of 
patients achieve a pathological complete response in the neoadjuvant setting [79, 80].  
2.2.2 Targeting HER2 in the Clinic 
Several targeted therapies are FDA approved for use in the clinic in combination 
with cytotoxic therapy to mediate the effects of HER2 overexpression in breast cancer 
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cells. Lapatinib (trade name Tykerb, Novartis, Basal, Switzerland) was the first receptor 
tyrosine kinase inhibitor approved for the treatment of HER2+ breast cancer in 2007 [81]. 
It is a small molecular therapy that targets both the epidermal growth factor receptor and 
HER2 tyrosine kinase domains [11]. Trastuzumab (trade name Herceptin, Genentech, 
South San Francisco, CA) is a humanized monoclonal antibody targeted against the 
extracellular domain IV of HER2. It inhibits downstream signaling reducing cell growth, 
promotes HER2 internalization and degradation, and attracts immune cells to tumors 
through antibody-dependent cellular cytotoxicity [23, 82, 83]. Pertuzumab (trade name 
Perjeta, Genentech, South San Francisco, CA) is also a humanized monoclonal antibody 
targeted to HER2, but binds to the extracellular domain II of HER2. Pertuzumab prevents 
downstream signaling by preventing HER2 dimerization [84].  Ado-trastuzumab 
emtansine (T-DM1) (trade name Kadcyla, Genentech, South San Francisco, CA) is an 
antibody-drug conjugate approved for use in patients that have previously been treated 
with trastuzumab and chemotherapy and have either metastatic or residual disease [85]. It 
consists of trastuzumab conjugated to a derivative of mertansine, which is a cytotoxic 
anti-microtubule agent. After T-DM1 binds to HER2, the receptor and T-DM1 are 
endocytosed and the cytotoxic agent causes cell cycle arrest and apoptosis [86].  
Trastuzumab, in addition to chemotherapy, is the first line of targeted treatment 
used in the clinic, although, depending on the stage at diagnosis and previous treatment 
received, other treatment plans may be used. Adding pertuzumab to trastuzumab and 
chemotherapy improved overall survival among patients with unresectable metastatic 
disease and when used in combination with trastuzumab in the adjuvant setting [87, 88].  
In patients who received neoadjuvant chemotherapy with trastuzumab and had residual 
invasive disease after surgery, adjuvant T-DM1 significantly lowered the risk of 
recurrence compared to trastuzumab [89]. Lapatinib (as well as other tyrosine kinase 
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inhibitors [90]) is approved for treatment of metastatic HER2+ breast cancer. It does not 
perform superior than trastuzumab in the clinic, but it can cross the blood brain barrier 
and can be a part of combination treatment for patients with brain metastasis [91, 92] .  
2.3 TUMOR INFILTRATING MYELOID CELLS 
2.3.1 Types and Functions 
Myeloid cells are a subset of leukocytes derived from hematopoietic stem cells in 
the bone marrow that are a part of the innate immune system [93, 94]. Subsets of myeloid 
cells include macrophages and dendritic cells and monocyte derived suppressor cells 
(MDSCs). Myeloid cells circulate through the body and are recruited when tissue is 
damaged or a foreign substance is present [95]. They can also home to tissues where they 
control cell turnover and maintain tissue homeostasis [96]. Myeloid cells are crucial in 
signaling T cells and promoting immune responses [97, 98].  
When dendritic cells are activated, they are primarily an antigen presenting cell. 
They phagocytose antigens, digest them into peptides and generate MHC molecules to 
present peptides to T cells, stimulating an adaptive immune response [98, 99]. 
Macrophages can also phagocytose foreign substances and present antigens to T cells 
[100]. Macrophages can broadly be categorized into two types, M1 and M2, and can 
switch between these two phenotypes in vivo [101]. MDSCs are a heterogeneous group of 
immature myeloid cells which can have two phenotypes, granulocytic MDSCs (G-
MDSCs) and monocytic MDSCs (M-MDSC).  
2.3.2 Role in the Tumor Microenvironment  
Myeloid cells in the tumor microenvironment greatly influence tumor progression 
and tumor response to treatment due to their critical involvement in angiogenic and 
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inflammatory responses [8–10]. M1 macrophages secrete pro-inflammatory cytokines 
and have a high antigen presentation ability which promotes T cell activation and anti-
tumor responses. M1 macrophages also have been shown to stabilize tumor vasculature 
[102–104]. Alternatively, M2 macrophages promote immunosuppression through the 
secretion of interleukin 4, 10 and 13. They induce angiogenesis through secretion of 
VEGF and several matrix metalloproteinases and have less antigen presentation ability 
than M1 macrophages [103, 105]. As solid tumors progress, macrophages are often 
skewed toward an M2 phenotype which promotes angiogenesis and immunosuppression 
leading to tumor escape [102]. Like M2 macrophages, MDSC’s secrete cytokines that 
inhibit anti-tumor immunity and promote tumor angiogenesis [106]. MDSCs can also 
down-regulate L-selectin on T cells; a key molecule that allows them to home to sites of 
damage or infection [107, 108]. Dendritic cells can enhance T cell responses to tumor 
cells, but only when they acquire a mature phenotype. Immature dendritic cells promote 
vascularization through proangiogenic cytokines such as VEGF and IL-8 [109]. 
Additionally, dendritic cell maturation can be prevented by immunosuppressive cytokines 
secreted from M2 macrophages or MDSC’s [110].  
2.3.3 Targeting Myeloid Cells 
Increasing evidence of myeloid cell modulation of cancer progression has led to 
efforts in developing myeloid targeted therapies. Drug development has been focused 
both in modulating the type of myeloid cell in the tumor microenvironment and in 
enhancing myeloid antigen presentation ability. Therapies to deplete TAM density or 
limit recruitment in cancers where TAM density is negatively correlated with tumor 
regression have had preclinical success [10]. Macrophage colony stimulating factor 1 
(CSF-1) is a primary regulator of macrophage differentiation and survival [111]. In a 
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xenograft mouse model of breast cancer, Aharinejad et al. showed that blocking CSF-1 
reduced macrophage infiltration and tumor burden [112]. However, therapies depleting 
macrophage tumor infiltration have not been successful in the clinic [113, 114]. One 
challenge with this type of therapy is targeting macrophages only in the tumor and not 
depleting them systemically [10]. Alternatively, strategies are being developed to skew 
macrophage polarization to an M1 phenotype in the tumor microenvironment or inhibit 
the function of immunosuppressive M2 macrophages [115–117]. 
Dendritic cell immunotherapy is another emerging treatment candidate. 
Granulocyte macrophage colony stimulating factor (GM-CSF) is a cytokine that can 
increase dendritic cell differentiation and activation [118, 119]. GVAX (originally 
developed at the Whitehead Institute of Biomedical Research) is a vaccine used to 
genetically modify pancreatic cancer cells to produce GM-CSF aimed in enhancing 
dendritic cell maturation [120]. Current clinical trials are being conducted using GVAX 
as a combination immunotherapy in pancreatic cancer at Johns Hopkins University / 
Sidney Kimmel Cancer Center [121]. Sipuleucel-T (trade name Provenge, Dendreon 
Pharmaceuticals, Seal Beach, CA) was approved for the treatment of metastatic prostate 
cancer in 2010 [122]. This therapy extracts immature dendritic cells from the patient, 
incubates them with GM-CSF and fragments of a prostate specific enzyme called 
prostatic acid phosphatase. Dendritic cells then mature in vitro, away from an 
immunosuppressive tumor microenvironment, and are re-administered into the patient 
[122, 123]. DC-Vax (Northwest Biotherapeutics, Bethesda, MD) is another autologous 
cell therapy used to stimulate dendritic cells in vitro and is currently in clinical trials to 
assess efficacy in brain, ovarian, prostate and multiple other solid tumor cancers [124]. 
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2.4 RADIATION THERAPY IN HER2+ BREAST CANCER  
2.4.1 Radiation in the Clinic 
Radiation therapy is given to breast cancer patients after a lumpectomy (surgery 
that removes the tumor while sparing healthy breast tissue) or mastectomy (surgery that 
removes the tumor and surrounding breast tissue). Almost all patients receive adjuvant 
radiation therapy regardless of the type of surgery they receive unless patients present 
with a low risk tumor (size < 2 cm and node negative) [24]. Radiation therapy is used to 
destroy any cancer cells that may be left in the breast tissue or chest wall after surgery 
and reduce the risk of locoregional recurrence. In the adjuvant setting, radiation is 
typically given in 2 Gy fractions, 5 days a week for about 5 weeks. Trastuzumab is 
administered every 3 weeks concurrently with radiation and can continue for up to a year 
[125]. There are recent investigations evaluating if radiation is needed to reduce 
recurrence in HER2+ patients, however, it is still currently used in the standard of care 
[126]. Clinical studies show recurrence in 5-15% of patients who receive radiation after 
surgery, and increase in risk is associated with tumor stage and HER2+ status [25, 26, 
127]. 
2.4.2 Resistance and HER2 
Ionizing radiation causes DNA damage through both indirect and direct effects. 
Direct effects are single or double-stranded breaks in cancer cell DNA caused by 
radiation therapy. Radiation causes indirect effects by breaking water molecules into 
fragments with unpaired electrons, called free radicals, which are highly reactive and can 
induce DNA damage [128]. The damage to DNA from radiation through either of these 
mechanisms can interfere with the ability of cells to properly replicate, and therefore, 
survive [128, 129]. The ability for cancer cells to survive radiation induced damage 
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depends largely on the induction of DNA repair signaling pathways. HER2+ breast 
cancer is reported to have an increased resistance to radiation treatment and studies show 
that pathways upregulated by HER2 ligand engagement can play a role in resistance [23, 
27, 29]. The PI3K/Akt/mTOR, activated through ligand engagement of HER2, controls 
regulation of genes responsible for DNA repair mechanisms such as Fanconi anemia 
group D2 protein (FANDCD2) and ribonucleotide reductase (RNR) [130, 131]. 
PI3K/Akt/mTOR pathway transduction also activates NF-κB which transcribes for genes 
including cyclin B1 and cyclin D1 that regulate DNA repair mechanisms to radiation 
therapy [29, 58, 132]. Although evidence supports PI3K/Akt/mTOR contributing to 
radiation resistance in HER2+ breast cancer, determining how to target this pathway to 





Chapter 3:  The Effects of IKK-beta Inhibition on Early NF-kappa-B 
Activation and Transcription of Downstream Genes1 
3.1 INTRODUCTION 
Nuclear factor kappa B (NF-κB) plays a key role in coordinating inflammatory 
responses through the regulation of genes, such as CXCL10, CCL5, and IL6, encoding 
pro-inflammatory cytokines, chemokines and growth factors [133–135]. Chronic 
inflammation promotes tumorigenesis by increasing cellular stress and DNA damage [2], 
and the appropriate regulation and control of NF-κB activity has long been considered a 
promising avenue for treating inflammatory diseases and cancer. Efforts in developing 
NF-κB pathway specific therapies have been largely unsuccessful due to its simultaneous 
influence in a vast number of physiological functions [17–19].  
NF-κB is activated by a variety of extracellular stimuli including interleukin 1 
beta (IL-1β) and tumor necrosis factor alpha (TNF-α), both playing roles in tumor 
progression and inflammation [45, 46, 136]. In resting cells, NF-κB is maintained in the 
cytoplasm by inhibitory kappa B (IkB) proteins [36, 137]. Upon stimulation, IκBs are 
phosphorylated by the IκB kinase complex (IKK), which causes its rapid degradation 
and releases NF-κB for nuclear translocation and subsequent control of gene 
transcription. IkB subunit beta (IKKβ) is one of the three kinases in IKK which is a 
convergence point for many NF-κB signaling pathways [36, 41]. Alterations of NF-kB 
signaling dynamics has been demonstrated as a function of  inhibiting IKK action [138–
                                                 
1Portions of this chapter were previously published in a peer-reviewed journal: Bloom MJ, Saksena SD, 
Swain GP, Behar MS, Yankeelov TE, Sorace AG. The effects of IKK-β inhibition on early NF- κB 
activation and transcription of downstream genes. Cellular Signalling. 2018. Bloom MJ designed and 
performed experiments, analyzed data, and wrote the publication.  
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141]. Additionally, dynamical changes of NF-κB activation have been shown to result in 
altered gene expression profiles [134, 138, 142]. However, the extent to which pathway 
perturbations effect signal dynamics and the relationship between NF-κB signaling 
dynamics and transcriptional output have not been fully elucidated. 
  In this contribution, we test the hypotheses that 1) inhibitors acting on pleiotropic 
pathway components can have stimulus-specific effects on signal dynamics, and 2) 
alterations in signal dynamics caused by small molecule inhibitors affect downstream 
gene transcription. To this end, we treated 3T3 fibroblasts with SC-514, an IKKβ 
selective inhibitor, and characterized changes in the temporal profile of NF-κB activity 
and corresponding gene expression in response to TNF-α or IL-1β stimulation. Taken 
together, the results in this study demonstrate the value of protein-specific small molecule 
inhibitors as tools for probing signaling pathways, and also highlight their potential for 
altering signal dynamics affecting gene expression as a result.   
3.2 MATERIALS AND METHODS 
3.2.1 Cell Culture 
3T3 mouse fibroblast cells were a gift from Dr. Laura Suggs (Department of 
Biomedical Engineering, University of Texas, Austin, TX) and were maintained in 
glucose-containing Dulbecco’s modified Eagle’s medium (DMEM, VWR International, 
LLC, Radnor, PA) supplemented with 10% bovine calf serum and penicillin-
streptomycin (100 units/ml).  One day before the stimulation experiments, cells were 
seeded in 8-well chambered cover glass (Cellvis, Mountain View, CA) in 200 μl of 
culture medium at an estimated 35,000 cells/well. Cell count was determined by the 
Countess II FL automated cell counter (Thermo Fisher Scientific Inc., Waltham, MA). 
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3.2.2 Stimulation Experiments 
3T3 fibroblasts in each 8-well chamber were pretreated with culture medium 
containing SC-514 (0, 10, 25, 50 or 100 µM) (Selleck Chemicals, Houston, TX) 1 hour 
prior to stimulation. SC-514 is a selective inhibitor of IKKβ action, inhibiting IkBα 
phosphorylation (when treated with SC-514 above 100 µM, cell dissociation occurred). 
Cells were stimulated with either 1 ng/ml of IL-1β, 10 ng/ml of TNF-α, or control saline 
for 5, 10, 15, 20, 25, 30, 45, 60, 75, or 90 min. An initial dose response experiment for 
each stimuli was conducted. The lowest concentration of stimuli that achieved the fastest 
rate of peak NF-κB activation was chosen for each stimuli. Cells were fixed and 
permeabilized with 100% methanol at -20 °C for 5 min and blocked in phosphate 
buffered saline (PBS, Caisson Laboratories, Inc., Smithfield, UT) + 2% bovine serum 
albumin (BSA, Fisher Scientific International Inc., Pittsburgh, PA) for 1 hour. Cells were 
incubated with NF-kB-p65 antibody Alexa Fluor 488 (AF488) conjugate (Cell Signaling 
Technology, Beverly, MA) in PBS+2% BSA for 1 hour followed by a 5-min incubation 
with 4',6-diamidino-2-phenylindole (DAPI) in PBS. This experiment was replicated for 
each drug treatment four times at each time point. A simplified diagram of the NF-kB 
signaling pathway can be seen in Figure 3.1. NF-kB is activated by both IL-1β and TNF-
α. When IL-1β and TNF-α bind to their receptors, (IL-1R and TNF-R, respectively), a 
series of phosphorylation events take place, eventually converging at the IKK complex 
which consists of three isoforms; IKKα, IKKγ, and IKKβ (Figure 3.1a). 
IKKβ phosphorylates an inhibitory protein IkBα, subsequently allowing NF-kB to 
translocate to the nucleus where gene transcription takes place (Figure 3.1b). NF-kB 
translocates back into the cytoplasm (Figure 3.1c) due to negative feedback in signaling.  
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Figure 3.1: High level representation of the NF-κB signaling pathway and SC-514 
mechanism of action. Stimuli IL-1β and TNF-α bind IL-1R and TNF-R, 
respectively, triggering downstream phosphorylation. NF-κB is sequestered 
in the cytoplasm by IkBα until activation of the IKK complex, which 
consists of three isoforms, IKKα, IKKγ, and IKKβ a). IKKβ phosphorylates 
IkBα, allowing NF-κB to translocate to the nucleus for gene transcription b) 
until eventually translocating back to the cytoplasm c). SC-514 is a selective 
inhibitor of IKKβ action. 
3.2.3 Microscopy and Image Analysis 
Cells were imaged in the green fluorescent protein (GFP) (Ex. 450-49 nm Em. 
500-550 nm) and DAPI (Ex. 325-375 nm Em. 435-485 nm) channels with the Leica 
DMI6000 microscope (Leica Microsystems, Wetzlar, Germany) at 20X resolution. Image 
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analysis was performed using CellProfiler (www.cellprofiler.org). An image analysis 
pipeline was constructed to measure DAPI-labeled nuclei and AF488-labeled NF-kB. 
Specifically, raw images were first corrected for uneven illumination (vignetting) [143–
145]. An illumination function was calculated using the intensity of each pixel (regular) 
and convex hull smoothing method of an empty field image was applied. Each image was 
divided with this illumination function and then background intensity was subtracted. All 
images were converted to grayscale. Nuclei were identified with the DAPI stain using 
Otsu two-class global thresholds. ‘Shape’ which identifies indentations on edges of 
touching cells was used to distinguish the number of objects in a clump. Cell boundaries 
were drawn using AF488-labeled NF-kB intensity, where boundaries are defined to be 
the dimmest points between two objects [143, 145]. The nucleus was masked from the 
whole cell to define the cytoplasm region. Intensity of AF488-labeled NF-kB was 
measured in the nucleus, cytoplasm, and whole cell. Each image was analyzed 
independently. Two 4.19 megapixel images were taken per well in each experiment with 
~100-200 cells in view in each image. Mean fluorescent intensity was calculated for each 
cell and averaged together for each well. Values were normalized to the averaged time 
zero intensity. Images where cell boundaries could not be accurately distinguished were 
eliminated from analysis.  
3.2.4 RNA Sample Preparation 
24 hours before RNA purification, 3T3 fibroblasts were plated in a 24 well plate 
at 140,000 cells/well. Cells were pretreated with culture medium containing SC-514 (0, 
10, 25, 50 or 100 µM) 1 hour prior to stimulation. Cells were stimulated with either 1 
ng/ml of IL-1β, or 10 ng/ml of TNF-α for 15, 30, 60, 120, and 360 min. All reagents for 
RNA purification were part of the RNeasy Mini kit (Quiagen, Hilden, Germany). Briefly, 
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cells were lysed directly in the 24 well plate and homogenized by vortexing. Precipitate 
was formed using 70% ethanol. All samples were treated with DNase and eluted into 30 
µl of RNase free water. RNA concentration and purity was determined using the Qubit 4 
Fluorometer (Thermo Fisher Scientific Inc., Waltham, MA).  This process was replicated 
for each drug treatment at each time point four times. 
3.2.5 TagSeq Profiling 
RNA TagSeq is a 3’ Tag-based approach to full RNA sequencing that has been 
proven highly reliable for differential gene expression analysis in well annotated 
genomes  [146, 147]. RNA samples were sent to the Genome Sequence and Analysis 
Facility at The University of Texas at Austin where libraries were constructed using a 
modified protocol from Lohman et al. [146]. Modifications from Lohman et al. included: 
i) Fragmentation of RNA was done using 5X First Strand Buffer (Takara Bio USA, Inc., 
Mountain View, CA) for 2.5 min ii) Titanium tag polymerase (Takara Bio USA, Inc., 
Mountain View, CA) was used in cDNA amplification master mix.   Samples were 
sequenced with the Illumina HiSeq 2500 1 × 100 with an average of 3.5 x 106 raw reads 
per sample.  
3.2.6 TagSeq Processing 
TagSeq clipping was carried out using FASTX-Toolkit’s fastx-clipper with 
parameters to remove non-template bases introduced by reverse transcriptase on the 5’ 
end [147, 148]. Quality assurance of processed reads was done using dispersion 
calculations implemented in DESeq2. Poor quality reads due to low amounts of sample 
(yield < 10 Mbp) for sequencing were removed from analyses (n = 2). Reads were 
aligned against an assembly of cDNA sequences for the GRCm38 (mm10) assembly 
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genome using Bowtie2 [149]. The output of processing was a count matrix of raw reads 
per gene for each experimental condition. 
3.2.7 Differential Gene Expression Analysis 
Differential expression analyses were carried out via DESeq2 from the 
Bioconductor suite of R tools [150] using count matrices generated from the processing 
pipeline. Normalization of reads was done by modeling read counts for each sample as 
following a negative binomial distribution with a mean that is proportional to the 
concentration of cDNA fragments from each gene scaled by a factor based on sequencing 
depth and library size. Expression differences were calculated by comparing coefficients 
in a generalized linear model (GLM) between experimental conditions. The GLM returns 
a coefficient matrix indicating overall expression strength of all genes in the sample and 
the shrunken (minimized dispersion) log2 fold change between two experimental 
conditions. Expression at each inhibitor concentration (25, 50, and 100 µM) for both IL-
1β and TNF-α at each longitudinal time point was individually compared against the no 
inhibitor condition at that same time point. All code for this portion of the analysis, 
including visualization of results, was written in R statistical software [151].3.2.8 
Technical Validation 
3.2.7.1 RNA Sample and Sequencing 
Quality assurance of all RNA samples was performed with the Qubit 4 
Fluorometer (Thermo Fisher Scientific Inc., Waltham, MA) to ensure high quality (RNA 
IQ > 9). After library preparation, select samples were again assessed to ensure high 
quality using the RNA integrity number (RIN > 7) with the Bioanalyzer 2100 (Agilent, 
Santa Clara, CA) and that every sample was an adequate concentration. Quality 
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evaluation of sequence reads was performed with a FastQC report24 (MultiQC version 
1.7). All samples had a Phred quality score above 30 across all bases up to 90 bp. At the 
end of the read (90-100 bp) where samples are known to be of lesser quality, all samples 
remained above 25 (Figure 3.2a). No median reached below 25 for a base and no lower 
quartile for any base was less than 10. The most frequently observed mean of per 
sequence quality scores was higher than 27 which equates to <0.2% error rate (Figure 
3.2b). Two samples yielded <10 Mbp and were recommended to be removed from 
analyses (n = 2). See Usage Notes for sample information. 
Figure 3.2: Quality assessment of sequencing data. A) Per base sequence quality scores 
across all samples. All scores remain above 25 for the entirety of the read. b) 
Per sequence quality scores across all samples. The most frequently 
observed mean quality was above 27.  
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3.2.7.2 Validation Across Replicates 
Each experimental condition had four biological replicates, enabling statistical 
evaluation to test if the data was robust to technical errors. Principal component analysis 
(PCA) was applied to the log-transformed gene expression space (Figure 3.3a and 3.3b). 
Clusters based on biological replicate are indicated by color. Two samples which were of 
poor quality due to experimental error are indicated with red arrows. Silhouette analysis 
[152] was conducted using the Euclidean distance between points within a given 
condition to validate consistency within the cluster. To calculate the silhouette of a point 
𝑖, 𝑠(𝑖) that lies within a cluster 𝐴, let the “within” dissimilarity metric 𝑎(𝑖) be defined as:  
 
(1)           𝑎(𝑖) = average Euclidean distance of point 𝑖 to all other points in cluster 𝐴 
 
Let 𝐶 be a set of all other clusters and the “between” dissimilarity metrics for 
point 𝑖, 𝑑(𝑖, 𝐶) be defined as:  
 
(2)       𝑑(𝑖, 𝐶) = average Euclidean distance of point 𝑖 to all points in set of clusters 𝐂 
Let 𝒃(𝒊) represent the closest neighboring cluster where: 
 
(3)            𝑏(𝑖) = min
𝐶 ≠ 𝐴
𝑑(𝑖, 𝐶)  
 












    if 𝑎(𝑖) < 𝑏(𝑖)




− 1    if 𝑎(𝑖) > 𝑏(𝑖)
       
 
Each silhouette measurement is a value between -1 and 1, where a value of 1 
indicates that a given point is well defined in the current cluster. A value of 0 indicates it 
is equally likely to be within its current cluster and its neighbor, and a value of -1 
indicates it is better classified in the neighboring cluster [152]. In our analysis, each 
cluster is given an average score of the silhouette measurement of all four biological 
replicates within the cluster. Two clusters stimulated with IL-1β resulted in negative 
average silhouette values (Figure 3.3a). See Table 3.1 for average silhouette values of the 
IL-1β stimulated condition. Three clusters stimulated with TNF-α resulted in negative 
average silhouette values (Figure 3.3b). See Table 3.2 for the average silhouette values of 








Table 3.2: Average silhouette values of TNF-α stimulated samples. 
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Dispersion on the log-transformed, non-dimensionally reduced data was 
calculated as the pairwise Euclidean distances between each sample represented as a 
vector of gene expression across all genes in the GRCm38 (mm10) genome (NCBI 
Assembly GCA_000001635.8). These pairwise distances were then displayed as a 
heatmap across samples for IL-1β stimulated samples (Fig 3.3c) and TNF-α stimulated 
samples (Fig 3.3d). Hierarchical clustering was also carried out to visualize clustering of 
biological replicates. This further corroborated statistical closeness of samples in each 




Figure 3.3: PCA and dispersion plots of RNA TagSeq data. a) PCA of IL-1β stimulated 
samples. b) PCA of TNF-α stimulated samples. Each color represents an 
experimental condition. Points represent biological replicates (n = 4 per 
condition). Samples determined to be of poor quality due to experimental 
error are indicated with red arrows. Conditions with negative average 
silhouette values are outlined in red. c) Heatmap representation and 
hierarchical clustering of dispersion statistics of IL-1β stimulated samples. 
d) Heatmap representation and hierarchical clustering of dispersion statistics 
of TNF-α stimulated samples. Gold indicates more highly correlated 
samples.   
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3.2.8 Statistical Analysis 
Analyses for fluorescent images were performed with MATLAB (MathWorks 
Inc., Natick, MA). Error bars in Fig. 2-6 represent 95% confidence intervals. Comparison 
of the mean fluorescent intensity between control and inhibitor treated data sets was 
determined with a two-way analysis of variance test (ANOVA). A pairwise t-test was 
used to determine significant differences in the fold change of peak intensity values. For 
cell measurements from the image analysis, outlier samples were determined statistically 
through the Grubbs outlier test and were eliminated from the data set. Analyses for gene 
expression were completed in R. Standard error for the GLM coefficient based log2 fold 
change estimates are calculated using the curvature of each coefficient’s posterior 
probability at the maximum of a density plot of coefficient estimates for log2 fold change. 
In DESeq2, p-values are generated using a Wald test and adjusted using Benjamini and 
Hochberg corrections [150]. 
3.2.9 Data Availability 
The CellProfiler image analysis pipeline is available upon request. All processing 
code used in TagSeq processing including RMarkdown files containing session 
information used in differential expression analysis is available at 
https://github.com/sachitsaksena/nfkb-tag-seq.  
3.2.10 Accession Numbers 
Mouse genome (GRCm38 (mm10)): GCA_000001635.8  
RNA TagSeq dataset deposited on NIH Sequence Read Archive: SRP163157 
NCBI Gene Expression Omnibus with accession number GSE129678 
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3.2.11 Usage Notes 
For pre-determined experimental low yield (corroborated by statistical analysis) 
samples 1-O-1 and 2-M-1 are recommended to remove from analyses. Removal of 
further samples should be done at the user’s discretion.  
3.3 RESULTS 
3.3.1 IKKβ inhibition causes significant differences in temporal profiles of nuclear 
NF-κB translocation when stimulated with IL-1β 
Representative images of NF-κB translocation after IL-1β stimulation at 0, 25, 45, 
and 90 min in three experimental conditions shown in Figure 3.4a.  A difference in 
nuclear accumulation of NF-κB can be seen between untreated cells and cells treated with 
25 µM of SC-514 at 25 and 45 min. An increased difference is apparent in cells treated 
with 100 µM of SC-514 and untreated cells at 25 and 45 min. At 90 min, NF-κB has 
cycled out of the nucleus and back into the   
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Figure 3.4: a) Representative images of NF-κB translocation over time. Row 1 shows 
untreated 3T3 fibroblast cells, while rows 2 and 3 display cells treated with 
25 and 100 µM of SC-514, respectively. All cells were stimulated with IL-
1β (1ng/ml) and fixed at 0, 25, 45, and 90 min. Visual differences in nuclear 
NF-κB translocation (stained green) can be seen between untreated cells and 
cells treated with 25 and 100 µM of SC514 at 25 and 45 min. b) 
Quantification of the mean nuclear NF-κB fluorescent intensity per each 
experimental condition. Nuclear and cytoplasmic regions were segmented 
from original immunofluorescence images and intensity values were 
averaged at each time point. Error bars represent 95% confidence intervals. 
A two-way analysis of variance test determined significant differences (P < 
0.05) between time series of untreated cells and cells treated with 25, 50 and 
100 µM of SC-514 (red).   
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cytoplasm in all experimental conditions. Statistical analyses revealed significant 
differences in time series between untreated cells and cells treated with 25, 50 and 100 
µM of SC-514 (P < 0.001) (Figure 3.4b, red). Time series data of cells treated with 10 
µM of SC-514 were also significantly different from cells treated with 25, 50, and 100 
µM of SC-514 (P < 0.001) but not so when compared to untreated cells (P = 0.224). 
Significant differences were also observed between cells treated with 25 µM and those 
treated with 50 or 100 µM of inhibitor (P = 0.027 and P < 0.001, respectively). 
Significant differences were also significant between cells treated with 50 µM and 100 
µM of inhibitor (P = 0.003). No concentration of inhibitor completely blocked nuclear 
translocation.  
3.3.2 IKKβ inhibition causes significant differences in temporal profiles of nuclear 
NF-κB translocation when stimulated with TNF-α 
Representative images of NF-κB translocation after TNF-α stimulation at 0, 25, 
45, and 90 min in three experimental conditions are shown in Figure 3.5a. A difference in 
the nuclear accumulation of NF-κB can be seen between untreated cells and cells treated 
with 25 µM of SC-514 at 25 and 45 min. An increased difference is apparent in cells 
treated with 100 µM of SC-514 at 25 and 45 min. At 90 min, NF-κB has cycled out of the 
nucleus and back into the cytoplasm in all experimental conditions. Statistical analyses 
revealed significant differences in time series between untreated cells and cells treated 
with 10, 25, 50 and 100 µM SC-514 (P < 0.001) (Figure 3.5b, red). Time series data of 
cells treated with 10 µM of SC-514 were also significantly different from cells treated 
with 50 and 100 µM of SC-514 (P = 0.012 and P < 0.001, respectively). Cells treated 
with 25 µM and 50 µM of SC-514 had significant differences when compared to cells 
treated with 100 µM of inhibitor (P < 0.001).  No significant differences were seen 
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between 10 µM and 25 µM conditions or 25 µM and 50 µM conditions (P = 0.585 and P 
= 0.091 respectively). No concentration of inhibitor completely blocked nuclear 
translocation. 
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Figure 3.5: a) Representative images of NF-κB translocation over time. Row 1 shows 
untreated 3T3 fibroblast cells, while Rows 2 and 3 display cells treated with 
25 µM and 100 µM of SC-514, respectively. All cells were stimulated with 
TNF-α (10 ng/ml) and fixed at 0, 25, 45, and 90 min. Visual differences in 
nuclear NF-κB translocation (stained green) can be seen between untreated 
cells and cells treated with 25 and 100 µM of SC514 at 25 and 45 min. b) 
Quantification of the mean nuclear NF-κB fluorescent intensity per each 
experimental condition. Nuclear and cytoplasmic regions were segmented 
from original immunofluorescence images and intensity values were 
averaged at each time point. Error bars represent 95% confidence intervals. 
A two-way analysis of variance test determined significant differences (P < 
0.05) between time series of untreated cells and cells treated with 10, 25, 50 
µM and 100 µM of SC-514 (red).   
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3.3.3 Degree of fold change in NF-κB nuclear translocation at peak activation is 
stimulus specific 
The dose response for fold change in the mean NF-κB nuclear intensity at peak 
time points is shown in Figure 3.5. Cells stimulated with IL-1β reach peak activation at 
45 min with a maximum fold change of 2.77 with no inhibitor (Figure 3.6a). There is a 
significant difference in intensity fold change between untreated cells and cells treated 
with 25 µM (P = 0.013) as well as 50 and 100 µM (P < 0.001) of SC-514 indicated with 
asterisks. Maximum difference in fold change is achieved with 50 µM of SC-514, 
reaching a fold change of 2.11, a 0.66 decrease from peak activation. There is no 
significant difference in peak activation between cells treated with 50 µM of inhibitor and 
100 µM of inhibitor (P = 0.554) suggesting saturation of the inhibitor effect.  Cells 
stimulated with TNF-α reach peak activation at 25 min with a maximum fold change of 
3.31 with no inhibitor (Figure 3.6b) There is a significant difference in intensity fold 
change between untreated cells and cells treated with 10, 25, 50 and 100 µM (P < 0.001) 
of SC-514 indicated with asterisks. Maximum difference in fold change is achieved with 




Figure 3.6: a) Mean nuclear intensity fold change of NF-κB translocation stimulated 
with IL-1β (1 ng/ml) at 45 min. Significant differences (P < 0.05) between 
untreated cells and cells treated with 25, 50, and 100 µM of SC-514 
indicated with asterisk. The maximum fold change difference in peak 
activation from untreated cells was achieved with 50 µM SC-514. b) Mean 
nuclear intensity fold change of NF-κB translocation stimulated with TNFα 
(10 ng/ml) at 25 min. Significant differences (P < 0.05) between untreated 
cells and cells treated with 10, 25, 50, and 100 µM of SC-514 indicated with 
asterisk. Maximum fold change difference in peak activation from untreated 
cells achieved with 100 µM of SC-514.  
3.3.4 RNA TagSeq data reveals temporal alterations in gene expression in response 
to stimuli 
Total number of significantly (P < 0.01) differentially expressed genes in cells 
treated with 25, 50 and 100 µM of SC-514 compared to untreated cells after stimulation 
with IL-1β are shown in Figure 3.7. For each individual time point, the number of 
differentially expressed genes increases with inhibitor concentration. Log2 fold changes 
in expression compared to untreated cells after stimulation with IL-1β of six 
inflammatory genes treated with 25, 50 and 100 µM of SC-514 are shown in Figure 3.7a. 
Significant differences in expression of cells treated with inhibitor from untreated cells 
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are shown in Figure 3.7b, red. Total number of significantly (P < 0.01) differentially 
expressed genes in cells treated with 25, 50 and 100 µM of SC-514 compared to 
untreated cells after stimulation with TNF-α are shown in Figure 3.8. For each individual 
time point, the number of differentially expressed genes increases with inhibitor 
concentration. Log2 fold changes in expression compared to untreated cells after 
stimulation with TNF-α of six inflammatory genes treated with 25, 50 and 100 µM of 
SC-514 are seen in Figure 3.8a. Significant differences in expression of cells treated with 
inhibitor from untreated cells are shown in Figure 3.8b, red. Expression of Interleukin 1 
receptor, type I (Il1r1) is downregulated in a dose dependent manner in cells stimulated 
with both IL-1β and TNF-α and has a consistent trend through time and between 
stimulation conditions. Early growth response 1 (Egr1) has a similar change in expression 
in both stimulation conditions, with the highest upregulation occurring at 15 and 120 min 
in a dose dependent manner. However, tumor necrosis factor alpha-induced protein 3 
(Tnfaip3) is significantly upregulated in cells stimulated with TNF-α at 15 min which is 
not the case in cells stimulated with IL-1β. Cytochrome c oxidase II, mitochondrial 
(Cox2) and Interleukin 6 (Il6) exhibit varying degrees of up- and down- regulation 
through time. Particular differences in Cox2 expression between stimuli are seen at 15 
min where IL-1β stimulated cells treated with 50 µM of inhibitor exhibit significant 
downregulation of expression while TNF-α stimulated cells do not and in expression of 
Il6 at 360 min where IL-1β stimulated cells treated with 25 µM exhibit an upregulation in 
expression and TNF-α stimulated cells do not. 
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Figure 3.7: a) Total number of significantly differentially expressed genes (P < 0.01) in 
cells treated with 25, 50 and 100 µM of SC-514 compared to untreated cells 
at 15, 30, 60, 120, and 360 min after IL-1β (1ng/ml) stimulation. An 
increasing number of differentially expressed genes is seen with increasing 
concentration of SC-514 for each individual time point. b) Log2 fold change 
in gene expression in cells treated with 25, 50 and 100 µM of SC-514 
compared to untreated cells for six inflammatory genes: Il1r1, Il6, Cox2, 
Nfkbia, Tnfaip3 and Egr1 at 15, 30, 60, 120, and 360 min after IL-1β 
(1ng/ml) stimulation. Significance (P < 0.05) indicated in red. Note vertical 
axis are different for each gene.  
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Figure 3.8: a) Total number of significantly differentially expressed genes (P < 0.01) in 
cells treated with 25, 50 and 100 µM of SC-514 compared to untreated cells 
at 15, 30, 60, 120, and 360 min after TNF-α (10 ng/ml) stimulation. An 
increasing number of differentially expressed genes is seen with increasing 
concentration of SC-514 for each individual time point. b) Log2 fold change 
in gene expression in cells treated with 25, 50 and 100 µM of SC-514 
compared to untreated cells for six inflammatory genes Il1r1, Il6, Cox2, 
Nfkbia, Tnfaip3 and Egr1 at 15, 30, 60, 120, and 360 min after TNF-α 
(10ng/ml) stimulation. Significance (P < 0.05) indicated in red Note vertical 
axis are different for each gene. 
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3.4 DISCUSSION 
Regulation of NF-κB is a critical step in inflammatory diseases and cancer. Pathway 
analyses are necessary to understand NF-κB transcriptional activity to aid in the 
development of targeted treatments. This study quantitatively evaluated the effect of SC-
514, a selective inhibitor of IKKβ, on NF-κB transcriptional activity using two stimuli, 
IL-1β and TNF-α. Results demonstrated significant temporal differences in NF-κB 
nuclear translocation between untreated cells and cells treated with various 
concentrations of SC-514 when stimulated with both IL-1β and TNF-α. Furthermore, this 
study identifies changes in inflammatory gene expression due to differing temporal 
profiles of NF-κB nuclear translocation of cells treated with IL-1β and TNF-α. 
 Protein- specific small molecules have been used to investigate signaling 
pathways and have proved valuable in developing targeted treatments [153]. These tools 
have allowed researchers to understand how specific signaling pathway perturbations 
alter genetic profiles and cellular function in disease states [138, 139, 153, 154]. Previous 
studies have shown altering upstream signaling events can effect NF-κB transcriptional 
activity [138–141],[155–157]. Our results corroborate this and further quantify these 
differences on a dose dependent level. A decrease in peak activation of NF-κB was seen 
even at low concentrations (i.e., 10 and 25 µM); however, there was never a complete 
blockade. Our results are in agreement with studies that show decreased activation of NF-
κB due to perturbations of the IKK complex [155–157]; however, the timing and degree 
of NF-κB inhibition varies in studies depending on the cell type and stimulus [138, 158]. 
This demonstrates how various cells can interpret signals independently and yield 
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different responses [159]. Cellular function must be taken into consideration when 
conducting pathway analyses in targeted drug development, as one pathway of interest 
may be present in multiple cell types relevant to the disease state. 
 The results of the present study show a stimulus specific response of NF-κB 
activation between cells stimulated with IL-1β and TNF-α supporting preliminary studies 
which investigated how targeting signaling dynamics through pharmacological 
intervention can produce stimulus-selective responses [17]. When stimulated with IL-1β, 
cells exhibit peak NF-κB activation at 45 min, a significant change in temporal profile 
starting with concentrations of 25 µM SC-514, and a maximum decrease in peak intensity 
with 50 µM of SC-514. These results show SC-514 blunts, in a concentration-dependent 
manner the amplitude of the transient peak of NF-κB activity induced by IL-1β 
stimulation. Interestingly, even at the highest dose, SC-514 does not change the timing of 
the signal decay. When stimulated with TNF-α, cells exhibit peak NF-κB activation at 25 
min, a significant change in temporal activation profile starting with 10 µM of SC-514, 
and maximum decrease in peak activation with 100 µM of SC-514. These results show 
SC-514 substantially re-modulates, in a concentration-dependent manner, the temporal 
dynamics of the NF-κB signal induced by TNF-α stimulation.  In contrast to the IL-1β 
case, IKK inhibition by SC-514 seem to affect both peak amplitude as well as the decay 
of the signal induced by TNF-α. These findings warrant further analyses quantifying the 
effect of SC-514 on additional pathway molecules, including IKK itself in this specific 
cell type, to determine other possible factors contributing to dynamical changes. 
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  Results from genetic sequencing yield results in agreement from others showing 
that manipulation of IKK leads to distinct NF-κB activation profiles and changes in gene 
expression profiles [134, 160], however our findings offer a further in depth analysis 
using longitudinal gene expression data with varying degrees of IKK inhibition in 
response to IL-1β and TNF-α. Overall, there is an SC-514 dose dependent trend of 
increasing differentially expressed genes through time. When looking at individual gene 
expression profiles through time, vast expression differences are observed in certain 
genes between experimental conditions.   
 Pathway perturbations can have differing effects on transcriptional activity 
depending on the stimuli present and is important to consider when designing therapeutic 
targets; in this application, especially in diseases where the inflammatory stimuli levels 
can vary such as cancer and rheumatoid arthritis [161, 162]. Our results not only 
elucidate differences in inflammatory gene expression between stimuli but also show 
how expression levels can change in a matter of minutes, demonstrating the need for 
further, highly time-resolved gene expression studies.  
 A limitation of this study is that analyses were performed at fixed times on 
populations of cells. Real time, single cell imaging data would better capture cell to cell 
heterogeneity and assess the signaling consequences from these differences. This study 
focuses specifically on NF-κB dynamical changes from IKK inhibition; monitoring 
pathway proteins upstream of NF-κB would offer additional insight on the mechanisms 
of these changes. Further studies should also investigate dynamical changes from 
pathway perturbations in the NF-κB network at later time scales and the differences that 
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arise in inflammatory gene expression. Additionally, our results would be further 
generalized if evaluated in other cell types. There may be differences between cell 
responses in the 3T3 cells used in these studies and primary cell lines. Studying the 
changes in signal dynamics due to pathway perturbations in vivo will increase biological 
insight of cellular behavior in disease states and prove valuable in pharmacology.  
3.5 CONCLUSION 
In summary, we demonstrate novel differences in early NF-κB transcriptional 
activity from IKKβ selective inhibition in response to IL-1β and TNF-α. Significant 
differences of NF-κB nuclear translocation were quantified at a high temporal resolution 
to both stimuli and revealed stimulus-specific responses to perturbation. Furthermore, 
gene expression profiles revealed an increase in significantly differentially expressed 
genes with increasing concentration of IKKβ inhibition. Individual inflammatory genes 
were up and down regulated with varying degrees calling for further analysis of specific 
genes of interest. This work analyzes changes in signaling and transcriptional dynamics 
necessary to develop effective NF-κB pathway targeted drugs and delineates the 
importance of pathway analyses in therapeutic design. 
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Chapter 4:  Anti-HER2 induced myeloid cell alterations correspond 
with increasing vascular maturation2 
4.1 INTRODUCTION 
Approximately one in five cases of breast cancer overexpress the human 
epidermal growth factor receptor 2 (HER2) [71]. Patients with HER2+ breast cancer have 
shorter disease free survival, decreased overall survival rates, and greater metastatic 
potential than HER2- patients [26, 76]. The current standard-of-care therapy for HER2+ 
breast cancer is cytotoxic chemotherapy in combination with trastuzumab, a targeted 
monoclonal antibody that binds to the HER2/neu receptor. Treatment with trastuzumab 
induces cell cycle arrest and inhibits cancer cell proliferation [23, 163]. Trastuzumab 
can also downregulate the expression of HER2 by promoting receptor internalization and 
degradation [83].  As a secondary effect, trastuzumab has been shown to alter the 
characteristics of tumor-associated vessels through increasing vascular maturation and 
stabilization in HER2+ tumors [21, 22, 164, 165]. Such changes can subsequently 
enhance the efficacy of combination therapies and improve treatment response in 
multiple types of cancer including breast, colon and lung [21, 166, 167]. With less than 
half of patients responsive to neoadjuvant therapy in HER2+ breast cancer, further 
understanding vascular changes that have potential to enhance therapeutic response 
may provide a clinically translatable benefit [80].  
Trastuzumab-induced vascular maturation is partly attributed to the decrease in 
vascular endothelial growth factor (VEGF) secretion, but the exact mechanisms have 
                                                 
2This chapter was submitted to a peer-reviewed journal: Bloom MJ, Jarrett AM, Triplett TA, Syed AK, 
Davis T, Yankeelov TE, Sorace AG. Anti-HER2 induced myeloid cell alterations correspond with 
increasing vascular maturation. Journal of Mammary Gland Biology and Neoplasia. 2019. Bloom MJ 
designed and performed experiments, analyzed data, and wrote the publication. 
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not fully been elucidated [21, 22, 164]. Clinical data evaluating progression-free survival 
from anti-angiogenic therapies targeting VEGF signaling pathways (such as 
bevacizumab) in breast cancer conflict between the United States and the European 
Union, but neither finds a significant improvement in overall survival rates [168–171]. 
One mechanism by which tumor cells can become resistant to anti-VEGF therapy is 
through the recruitment of pro-angiogenic, immunosuppressive myeloid cells [172, 173]. 
Myeloid cells are non-lymphoid immune cells that influence the development of tumor 
vasculature through the secretion of pro- and anti-angiogenic factors [174, 175]. When 
anti-VEGF therapies are administered at high doses or for a prolonged period of time, 
tumor vasculature is overly pruned and leads to tumor hypoxia and upregulation of 
hypoxia inducible factors (HIFs) [173, 176]. HIFs drive recruitment of tumor associated 
macrophages (TAMs), myeloid derived suppressor cells (MDSCs), and prevent 
maturation of dendritic cells [174, 177, 178]. Angiogenesis is then driven by myeloid 
cells through both VEGF dependent and independent pathways enhancing tumor 
progression [172, 173]. However, when tumor vasculature is normalized, tumor hypoxia 
decreases, and the balance of angiogenic factors in the tumor microenvironment can be 
restored through the reprogramming of the myeloid cell population—further stabilizing 
the vasculature and promoting antitumor responses [179, 180]. Both clinical and 
preclinical studies show that treatment with trastuzumab alters immune infiltration 
(including myeloid populations) in HER2+ tumors [181–183]; however, to our 
knowledge, a detailed immune panel in HER2+ breast cancer identifying changes in 
myeloid populations to trastuzumab has not been conducted.  
Our previously acquired immunofluorescence data revealed an increase 
specifically in the macrophage population after trastuzumab treatment [183]. TAMs are a 
significant component of the breast tumor microenvironment and of particular interest 
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due to their influence in tumor progression and response to treatment [184, 185]. 
TAMs largely polarize towards two phenotypes, “classical” (M1) or “alternative” (M2) 
depending on the stimuli present in the tumor microenvironment and have been shown to 
either enhance (M1) or suppress (M2) anti-tumor immune responses [101, 186].  
Macrophage differentiation towards the M2 phenotype are driven by interleukin 4 (IL-4) 
and interleukin 13 (IL-13); and promote angiogenesis by secreting VEGF, basic 
fibroblast growth factor, and several matrix metalloproteases (MMPs) [102, 103, 105]. 
Macrophages are polarized towards an M1 phenotype by lipopolysaccharide and 
interferon gamma (IFN-γ). They have a lower angiogenic potential than M2 macrophages 
and promote anti-tumor immunity through secretion of pro-inflammatory cytokines and 
increased antigen presentation ability [102–105].  
In this study, we sought to gain insight into the mechanisms of improved tumor 
vascularization and heightened windows of anti-tumor immunity after administration of 
trastuzumab. First, we evaluated immune modulation by quantifying the number of 
macrophages with an M2 phenotype to an M1 phenotype following treatment in a 
xenograft model by flow cytometry and validated concurrent vascular alterations using 
quantitative histology. Finally, we identify changes in tumor cytokines and 
chemokines relating to immunity and angiogenesis through a multiplex immunoassay.   
4.2 MATERIALS AND METHODS 
4.2.1 Cell Culture 
BT474 breast cancer cells were purchased from ATCC (Manassas, 
Virginia). Cells were cultured in improved minimal essential medium (IMEM, 
Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 1% penicillin/streptomycin, and 
20 g/mL insulin. Cells were grown at 37 °C with 5% CO2. Cells were cultured to 70-
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80% confluency and all cell counts were determined by the Countess II FL automated 
cell counter (Thermo Fisher Scientific Inc., Waltham, MA).   
4.2.2 Animal Procedures 
All procedures were approved by our institution’s animal care and use committee. 
Female nude athymic mice (N = 56) were purchased from The Jackson Laboratory (Bar 
Harbor, ME) at 3-4 weeks of age. After a one-week acclimation period, mice were 
subcutaneously implanted with a 0.72 mg, 60-day release, 17β-estradiol pellet 
(Innovative Research of America, Sarasota, FL) in the nape of the neck. 24 hours later, 
107 BT474 breast cancer cells in 100 μl serum-free IMEM media with 30% growth 
factor-reduced Matrigel were injected subcutaneously into the right flank of the mouse. 
Tumors were grown to approximately 250 mm3 (estimated 8-10 weeks) at which point 
the animals were entered into the study. Animals were randomly sorted into treatment 
groups and administered either trastuzumab (10 mg/kg) or saline on three different days 
(Days 0, 3 and 6) via intraperitoneal (IP) injection during a week-long treatment plan. 
Mice were euthanized for tissue processing on days 0 (N = 5), 4 (N = 6 control, N = 6 
treated) and 7. Mice taken down on Day 7 either received two total doses of treatment on 
Days 0 and 3 (N = 6 control, N = 5 treated) or three total doses of treatment on Days 0, 3 
and 6 (N = 5 control, N = 6 treated) (Figure 4.1).  
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Figure 4.1: Outline of experimental procedure and treatment schedules. BT474 HER2+ 
tumor-bearing mice were divided into four treatment groups. Tumors were 
extracted from group 1 on Day 0 without treatment. Group 2 and 3 received 
two doses of saline (Control) or trastuzumab (Treated) on Days 0 and 3 and 
tumors extracted on Day 4 (group 2) and Day 7 (group 3). Group 4 received 
three doses of saline or trastuzumab on Days 0, 3 and 6 and had tumors 
extracted on Day 7. 
4.2.3 Spleen Disaggregation 
The spleen was excised and immediately placed on ice in RPMI 1640 serum free 
media (Caisson Laboratories, Smithfield, UT). All further incubation periods and 
reagents were at 4°C. The spleen was then homogenized to a single cell suspension and 
diluted in flow wash buffer (FWB, PBS + 1% FBS + 5mM EDTA). Cells were 
resuspended in 1× red blood cell (RBC) lysis buffer (Biolegend, San Diego, CA) for 3 
minutes. The cell suspension was washed in FWB and filtered through a 70 μM strainer.  
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4.2.4 Tumor Disaggregation 
One hour prior to mouse sacrifice, each mouse received 60 mg/kg of 
pimonidazole (Hypoxyprobe, Inc., Burlington, MA) in a 100 μl intravenous injection. 
After tumor excision, the tissue was cut at the longest cross-section and half was placed 
in a tissue cassette and incubated in 10% neutral buffered formalin (Fisher Scientific 
International Inc., Pittsburgh, PA) for 48 hours. Samples were then transferred to 70% 
ethanol and prepped for immunohistochemistry (IHC) staining. The other half of the 
tumor was cut into 2-3 mm pieces and placed in 0.15% collagenase type IV (Worthington 
Biochemical Corporation, Lakewood, NJ) with 5 mM Ca2 at 1 mL/100 mg of tissue. 
Mechanical dissociation was performed using the gentleMACs dissociator (Miltenyi 
Biotec, Bergisch Gladbach, Germany). Samples were incubated while rotating at 37°C 
for 45 minutes. After digestion, the suspension was washed in FWB and resuspended in 3 
mL of 1× RBC lysis buffer for 3 minutes on ice. Cells were washed in FWB and filtered 
through a 70 μM strainer.  
4.2.5 Flow Cytometry 
Cells harvested from the spleen were used for single color controls and multi-
color staining control. Control and tumor samples were resuspended at a concentration of 
106 cells/100 L in FWB in round bottom polystyrene tubes. Cells were stained with the 
following antibody fluorophore conjugates: CD45-PerCP/Cy5.5, CD11c-Pacific Blue, 
CD11b-AF700, MHCII-APC/Cy7, Ly6c-BV510, Ly6g-APC, CD38-FITC (Biolegend, 
San Diego, CA), F480-PE/Cy7 (Tonbo Bioscences, San Diego, CA), CD206-PE (R&D 
Systems, Minneapolis, MN) and propidium iodide (PI, Enzo Life Sciences, Farmingdale, 
NY). All antibody staining took place for 30 minutes at 4°C in the dark. For all 
experiments, cells were acquired on the BD LSRII Fortessa flow cytometer. 
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Compensation and sequential gating was performed with FlowJo software (FlowJo LLC, 
Ashland, OR). Populations of myeloid cells that were identified included macrophages, 
dendritic cells, granulocytic myeloid derived suppressor cells (G-MDSC), monocytic 
myeloid derived suppressor cells (M-MDSC) and M0, M1 and M2 macrophage 
phenotypes (Figure 4.2).  
 
Figure 4.2: Gating strategy for all flow cytometry samples. Cell debris and cell doublets 
were eliminated using forward scatter (FSC) and side scatter (SSC). Live 
cells were identified as negative for propidium iodide signal. Immune cells 
were gated as CD45+. Macrophages were gated using F480+ and MHCII+. 
Macrophage phenotypes were identified as the following: M0 (CD38-
/CD206-), M2 (CD38-/CD206+), Co-Expression (CD38+/CD206+) and M1 
(CD38+/CD206-). Non-macrophages were further identified as dendritic 
cells (CD11c+/MHCII+). MDSC were identified as CD11b+ with Ly6g+ 
indicating G-MDSC, and Ly6g- indicating M-MDSC.  
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4.2.6 Immunohistochemistry 
Formalin fixed tumor sections were embedded in paraffin. Tumors were then 
sliced into 4 μM sections and stained for the following: hematoxylin and eosin (H&E), 
mouse anti-CD31, mouse anti-α-smooth muscle actin (α-SMA, Abcam, Cambridge, UK), 
mouse anti-F480 (Invitrogen, Carlsbad, CA), and human anti-Ki67 (R&D Systems, 
Minneapolis, MN). Immuno-stained slides were scanned (20×, 0.495 μm/pixel) with the 
Aperio ScanScope (Leica Microsystems, Wetzlar, Germany). Automated segmentation of 
tissue structure was completed using custom MATLAB algorithms (MathWorks Inc., 
Natick, MA). All images were uniformly segmented based on thresholds determined 
from positive and negative controls for each stain except for regions of necrosis, which 
were determined manually from H&E staining. Images were registered to the 
corresponding H&E stained image from that sample. For registration, images were 
converted to grayscale. Transformations applied to images consisted of translation, 
rotation and scale (similarity) based on intensity differences. A viable tissue mask was 
defined as total tumor area minus necrotic area.  Macrophage infiltration (F4/80) was 
defined as the percent of positive stain per viable tissue area. Microvessel density (CD31) 
and vascular smooth muscle coverage (α-SMA) were calculated as the number of vessels 
per mm2 of tumor tissue. The vessel maturation index was evaluated as the ratio of α-
SMA coverage to microvessel density [187]. To confirm treatment response, proliferation 
(Ki67) was defined as the percent of total tumor nuclei positively stained. All codes are 
available upon request. 
4.2.7 Cytokine Detection Assay 
Tumor bearing mice (n = 10) were treated with either three total doses of 
trastuzumab (10 mg/kg) or saline for 1 week on Days 0, 3 and 6. On Day 7, tumors were 
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excised and flash frozen with liquid nitrogen in Optimal Cutting Temperature 
compound (Tissue-Tek; Sakura Finetek USA). Tumors were lysed in Cell Lysis Buffer 2 
(R&D Systems, Minneapolis, MN). Samples were concentrated using Pierce Protein 
Concentrator PES 3K (Thermo Fisher Scientific Inc., Waltham, MA), and original 
sample protein concentration was determined using the NanoDrop 2000 (Thermo Fisher 
Scientific Inc., Waltham, MA). The multiplex assay was conducted using the Bioplex 200 
(BioRad Laboratories, Hercules, CA). Samples were incubated with premixed beads 
targeted to 12 different analytes according to the Mouse Magnetic Luminex Assay (R&D 
Systems, Minneapolis, MN) specifications. Protein concentrations were determined using 
corresponding standard curves for each analyte (Figure 4.3).  
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Figure 4.3: Standard curves for multiplex cytokine assay. 
4.2.8 Statistical Analysis 
Statistical analysis was conducted using MATLAB (MathWorks Inc., Natick, 
MA). Statistical differences between treatment groups of flow cytometry, 
immunohistochemistry, and cytokine data were determined using a nonparametric 
Wilcoxon rank sum test. All data is presented as mean ± standard error with P ≤ 0.05 
indicating significance. Linear regression parameters and Pearson correlation coefficients 
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were determined for flow cytometry and histology comparisons. Tumors were eliminated 
from analysis if viability was < 50% due to prolonged incubation as determined with 
live/dead stain in flow cytometry (N = 4), or if ≥ 4 myeloid cell populations were 
significant outliers (N = 3). Outliers were defined as a value more than three absolute 
deviations from the median.  
4.3 RESULTS 
4.3.1 Macrophage infiltration increases transiently after trastuzumab treatment 
Flow cytometry data revealed increased tumor macrophage infiltration 24 hours 
after trastuzumab treatment compared to controls (Fig. 4.4a). On Day 4, 24 hours after 
the second dose of trastuzumab, the percent of macrophages making up the tumor-
infiltrating immune cells increased from 30.52 ± 5.34% in control to 45.87 ± 2.1% in 
treated mice (P = 0.02). On Day 7, 96 hours after two doses of trastuzumab, no 
significant difference was seen between control (29.97 ± 6.63%) and treated (20.31 ± 
5.3%) tumors of that group (P = 0.43). On Day 7, 24 hours following a third doses of 
trastuzumab, the macrophage population increased from 26.54 ± 6.54% in control tumors 
to 50.05 ± 5.14% in treated tumors (P = 0.03). Populations of dendritic cells (Figure 
4.4b), G-MDSC (Figure 4.4c) and M-MDSC (Figure 4.4d) were quantified in all 
treatment groups; however, no significant differences were observed.  
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Figure 4.4: Macrophage infiltration increases 24 hours after administration of 
trastuzumab. a) Percent of total macrophages in the tumor immune 
population is shown, revealing a significant increase in macrophage 
infiltration on Day 4 (P = 0.02) and Day 7, 24 hours after treatment (P = 
0.03) compared to control tumors. Percent of b) dendritic cells, c) G-MDSC 
and d) M-MDSC is shown in the tumor immune population (no significant 
differences were observed between control and treated tumors). 
4.3.2 M1 macrophage phenotype becomes more abundant in tumors over the course 
of trastuzumab treatment 
 Representative flow cytometry data plots of changes in M0 (CD38-/CD206-), M1 
(CD38+/CD206-), M2 (CD38-/CD206+) [188, 189] macrophage subtypes and co-
expression (CD38+/CD206+) over the course of trastuzumab treatment are shown in 
Figure 4.5a. While control tumors were consistent between treatment groups, tumors co-
expressing CD38 and CD206 increased on Day 4 (24 hours after a second dose of 
trastuzumab) from 27.1 ± 4.12% to 56.9 ± 8.82% (P = 0.02) (Figure 4.5b). No differences 
were seen in co-expression between control and treated tumors in the other treatment 
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groups. After a third dose of trastuzumab was given, the percent of M1 macrophages 
significantly increased from 13.38 ± 3.65% to 31.07 ± 2.9% (P = 0.02) (Figure 4.5c). 
There was a decrease in non-differentiated M0 macrophages on Day 4 from 45.36 ± 
6.13% in control tumors to 19.03 ± 4.53% in treated tumors (P = 0.02) and on Day 7, 24 
hours after treatment from 52.44 ± 9.82% to 34.08 ± 2.74% (P = 0.03) (Figure 4.5d). No 
significant differences were observed in the percent of M2 macrophages across treatment 
groups (Figure 4.5e). In control and treated spleens taken down at Day 4, there were no 
statistical differences between macrophage populations (Figure 4.6) that suggests this 
effect is tumor specific. 
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Figure 4.5: Macrophage phenotypes transition over the course of trastuzumab treatment. 
a) Representative flow cytometry graphs of Day 0 control tumors and Day 4 
and Day 7 trastuzumab treated tumors (96 and 24 hours after treatment). 
Visual increases are observed in CD38+/CD206+ co-expressing 
macrophages on Day 4, 24 hours after treatment and CD38+/CD206- M1 
macrophages on Day 7, 24 hours after trastuzumab treatment. b) Percent of 
macrophages co-expressing CD38 and CD206 is shown revealing a 
significant increase (P = 0.02) from control in Day 4 treated tumors, after 
two doses of trastuzumab. c) Percent of macrophages with an M1 phenotype 
(CD38+/CD206-) is shown revealing a significant increase (P = 0.02) in the 
M1 macrophage population in treated Day 7 tumors after three doses of 
trastuzumab. d) Percent of macrophages with a non-differentiated, M0 
phenotype (CD38-/CD206-) is shown revealing a significant decrease in 
population observed on Day 4 (P = 0.02) and Day 7 (P = 0.03), 24 hours 
after treatment. e) Percent of M2 macrophages (CD38-/CD206+) (no 
significant differences were observed between control and treated tumors). 
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Figure 4.6: Spleens taken from control and treated mice on Day 4, 24 hours after 
trastuzumab treatment. No significant differences (P > 0.05) were observed 
in G-MDSC, M-MDSC, dendritic cells, macrophages, M2, Co-Expression, 
M1 or M0 populations. (N = 5 control, N = 4 treated).  
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4.3.3 Vessel maturation index increases over the course of trastuzumab treatment 
and correlates with increasing M1 macrophage populations 
Representative images of F4/80 staining in control and treated Day 4 tumors are 
shown in Figure 4.7a. Comparison between percent F4/80+ cells in flow cytometry 
analysis and percent area F4/80+ in corresponding tumor central slices showed a 
significant positive linear correlation (R = 0.35, P = 0.03) (Figure 4.7b). Representative 
images of CD31 and α-SMA in control and treated Day 4 tumors are shown in Figure 
4.8a. No significant differences in microvessel density or α-SMA coverage were 
observed between control and treated tumors (Figure 4.8b and 4.8c, respectively). The 
vessel maturation index increased on Day 7 after three doses of trastuzumab from 11.13 ± 
1.90% for control tumors to 22.58 ± 3.17% for treated tumors (P = 0.04) (Figure 4.8d). 
Comparison of vessel maturation and percent M1 macrophages from flow analysis 




Figure 4.7: Correlation between F4/80+ determined by flow cytometry and IHC staining. 
a) Representative IHC stained images of F4/80 in Day 4 control (top) and 
trastuzumab treated (bottom) tumors. b) Linear correlation between percent 
of total cells F4/80+ as determined by flow cytometry and percent of total 
tumor area F4/80+ determined by IHC staining in the corresponding tumor 
central slice showing a positive linear correlation (R = 0.35, P = 0.03). 
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Figure 4.8: Vascular changes over the course of trastuzumab treatment positively 
correlate with macrophage phenotypic alterations. a) Representative images 
of CD31 (top) and α-SMA (bottom) in Day 4 control and trastuzumab 
treated tumors. b) CD31 microvessel density and c) α-SMA coverage in 
control and trastuzumab treated tumors (no significant differences were 
observed). d) Vessel maturation index as determine by ratio of α-SMA to 
CD31 microvessel density in control and trastuzumab treated tumors is 
shown, revealing a significant increase in vessel maturation index on Day 7, 
24 hours after a third dose of trastuzumab (P = 0.04). e) Linear correlation 
between vessel maturation index and percent M1 macrophages in 
corresponding tumor halves as determined by flow cytometry showing a 
positive linear correlation (R = 033, P = 0.04).  
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4.3.4 Trastuzumab induced changes in inflammatory cytokines 
To determine if cytokine differences were also present in tumors that displayed a 
higher percentage of M1 macrophages, a cytokine multiplex assay was conducted to 
evaluate differences between control and treated tumors on Day 7, 24 hours after being 
treated with three doses of trastuzumab (Figure 4.9). Treated tumors had a significant 
decrease in the pro-angiogenic factor VEGF-A (P = 0.008) and increases in pro-
inflammatory cytokines TNF-α and IL-1β (P = 0.024 and 0.032, respectively). Significant 
increases in chemokines CCL21 (P = 0.016), CCL7, and CXCL10 (P = 0.008) were also 
seen in treated tumors compared to control. Changes in IL-6, IL-4, IL-10, IL-13, IL-23, 
and MMP-12 were evaluated, but no significant differences were found between control 





Figure 4.9: Continued trastuzumab treatment induces changes in tumor cytokine levels. 
Day 7 control and trastuzumab treated tumors (24 hours after three doses of 
treatment) were evaluated for murine VEGF-A, TNF-α, IL-1β, CCL21, 
CCL7, and CXCL10 cytokine levels. A significant decrease in VEGF-A (P 
= 0.008) was observed in treated tumors compared to control. A significant 
increase in TNF-α (P = 0.024), IL-1β (P = 0.032), CCL21 (P = 0.016), 





4.3.5 Validation of treatment response and necrosis in control and treated tumors 
Representative images of Ki67 and H&E stains are shown in Figure 4.10a. 
Treatment response was confirmed in all treatment groups indicated by significant 
decreases in Ki67 expression (Figure 4.10b). Day 4 trastuzumab treated tumors had an 
average Ki67 expression of 12.41 ± 2.06% while control tumors showed 27.66 ± 2.33% 
(P = 0.03). Treated tumors taken down on Day 7 after two doses of trastuzumab had 
13.77 ± 1.56% Ki67+ nuclei compared to 24.40 ± 1.34% (P = 0.05) in control tumors. 
Tumors taken down on Day 7 after three doses of trastuzumab had 19.15 ± 2.66% Ki67+ 
nuclei compared to 28.70 ± 2.48% (P = 0.03) in Day 7 control tumors. No significant 





Figure 4.10 Quantitative analysis of Ki67 and necrosis in IHC stained samples. a) 
Representative images of Ki67 (top) in control and treated Day 4 tumors are 
shown. Necrotic sections from H&E (bottom) indicated with black arrow in 
control and treated Day 4 tumors. b) Percent nuclei Ki67+ in control and 
trastuzumab treated tumors. In all treatment groups, there was a significant 
decrease (P ≤ 0.05) in Ki67+ nuclei, validating treatment response. c) 
Percent necrotic area in control and treated tumors (no significant 
differences were observed between control and treated tumors).  
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4.4 DISCUSSION 
There is a well-developed field focused on exploiting vascular maturation to 
improve the response of cancers to therapy [166, 167, 176, 190]. Vascular maturation 
promoted by anti-HER2 targeted therapy with trastuzumab has been shown to enhance 
response to combination paclitaxel and doxorubicin chemotherapy in mouse models of 
breast cancer [21, 165]. Identifying underlying mechanisms of vascular changes will 
benefit clinical treatment regimens by elucidating methods to enhance and sustain 
vascular perfusion for improved drug delivery. Determining immune related mechanisms 
of vascular maturation could offer clinical benefit in developing combination 
immunotherapy treatments with trastuzumab. The present study evaluated trastuzumab 
induced changes of myeloid cell infiltration in a murine model of HER2+ breast cancer.  
Our results demonstrated continuous trastuzumab treatment alters pro-inflammatory 
innate immune components of the tumor microenvironment while simultaneously 
increasing vascular maturation.  
Immunophenotyping by flow cytometry revealed a transient increase in 
macrophage infiltration in treatment groups that were evaluated 24 hours after 
administration of trastuzumab (Figure 4.4a). With continued treatment, macrophages 
transitioned to an M1 phenotype (Figure 4.5c). When treatment stopped for four days, 
macrophages reverted to phenotypes similar to those found in control tumors. The results 
from our study showed an increase in M1 macrophage population positively correlating 
with an increase in vascular maturation after persistent trastuzumab treatment (Figure 
4.8e). Similarly, in a murine model of pulmonary fibrosarcoma, Rolny et al. showed that 
genetically inducing tumor production of histidine-rich glycoprotein (HRG) inhibited 
tumor growth and metastasis, and where HRG only sustained vascular normalization 
through the polarization of M1 macrophages [180]. Furthermore, Huang et al. found that 
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low dose anti-VEGF receptor 2 therapy normalized tumor vasculature and polarized 
TAMs towards an M1 phenotype and improved response to combination immunotherapy 
in mouse models of breast cancer [179]. Additional studies depleting macrophages from 
the system used in our study would offer further quantitative information on macrophage 
contribution to vascular maturation and tumor response.   
The changes in cytokine profiles of trastuzumab treated tumors support the results 
from immunophenotyping and histological evaluation. Our study revealed a decrease in 
host VEGF-A and simultaneous increases in several pro-inflammatory cytokines and 
chemokines (Figure 4.9), which agrees with what has been previously shown [21]. 
VEGF-A is a key regulator of angiogenesis and decreases in VEGF-A aligns with the 
increase in vascular maturation evaluated by histology with continued treatment of 
trastuzumab (Figure 4.8d). In conjunction with an increase in total macrophage 
infiltration 24 hours after treatment, there was a simultaneous decrease in non-
differentiated, M0 macrophages (CD38-/CD206-) (Figure 4.5d). This could in part be due 
to changes in inflammatory cytokines and chemokines in the tumor microenvironment 
(Figure 4.9). M1 macrophages secrete increased amounts of TNF-α and IL-1β over M2 or 
M0 macrophages [101]. With continued treatment of trastuzumab, by Day 7 we see an 
increase in M1 macrophages (Figure 4.5c) and increases in TNF-α and IL-1β (Figure 
4.9). Chemotaxis is induced differently in M1 and M2 macrophages. In this study, 
CXCL10, CCL21 and CCL7 were both upregulated in trastuzumab treated tumors. 
Others have found CXCL10 and CCL21 to induce chemotaxis specifically in M1 
macrophages [191, 192]. Studies show CCL7 can induce chemotaxis in both M1 and M2 
macrophages [192, 193]. Although the changes in cytokines of the tumor 
microenvironment support the observed changes in macrophage phenotypes, many of the 
molecules can have both pro- and anti- tumor effects. Additional studies are needed to 
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fully understand the underlying mechanisms cytokine treatments have to skew the 
inflammatory and angiogenic potential of tumors.     
In the clinic, TAMs are being investigated as prognostic and diagnostic 
biomarkers [10, 194, 195]. In several cancers, including breast, TAM density correlates 
with worse overall survival rates [10, 196]; however, TAM phenotypes can influence 
response to treatment. A recent study conducted in patients with stage II colon cancer 
showed that patients with a high M2/M1 (CD206+/CD68+) macrophage ratio were more 
likely to benefit from adjuvant chemotherapy than patients with a low M2/M1 ratio, who 
did not show any clinical benefit—therefore, identifying a subset of patients that would 
not need additional treatment following surgery [197]. Clinical trials with therapies 
inhibiting tumor macrophage recruitment to solid tumors have not been successful in 
showing improved tumor response [113, 114]. Ongoing preclinical and clinical work is 
being done in identifying drug targets that can reprogram immunosuppressive 
macrophages [115–117]. This study shows preliminary evidence that trastuzumab, 
already used in the clinic to treat HER2+ breast cancer, has the potential to repolarize M2 
macrophages towards an M1 phenotype.   
 A limitation of this study is that mice were taken down at fixed time points and 
measurements could not be made longitudinally in the same animal. However, our 
methods allowed for an extensive immunophenotyping panel and simultaneous analyses 
of vascularity from central slice immunohistochemistry staining. Noninvasive imaging, 
such as immuno-PET imaging, is an alternative method that could give more finely time 
resolved data of immune infiltration after treatment, although it would only allow for 
measurement of one target at a time and may lack the spatial resolution required to fully 
assess immune response.  
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Although a xenograft model was used in this study, murine macrophages do 
respond to trastuzumab (primarily through the FcγIV receptor [198]) and no significant 
differences in macrophage quantities or phenotypes were observed between spleens of 
Day 4 control and treated mice, showing immune response was directly tumor associated 
(Supplementary Fig. S3). The results from this study motivate future research in mouse 
models with intact (or humanized immune systems) to further characterize trastuzumab 
induced immune infiltration. Determining effective markers to distinguish M1/M2 
macrophage phenotypes is an active area of research [199, 200]. Two other markers 
considered for this study were inducible nitric oxide synthase (iNOS, M1 expressed) and 
early growth response protein 2 (Egr2, M2 expressed) [199]. The distribution of 
macrophage phenotypes in Day 0 control spleens did not differ using iNOS and Egr2 
from using CD38 and CD206, and the latter were chosen for this study. Computational 
methods that analyze multidimensional flow cytometry data could be used in the future to 
analyze a panel with several macrophage markers to identify further phenotype subsets 
(i.e. M2a, M2b, M2c).  
4.5 CONCLUSION 
In summary, this study identified novel differences in myeloid cell infiltration 
between control and trastuzumab treated tumors. With continued treatment, TAMs 
polarized to a pro-inflammatory M1 phenotype and increased macrophage transitioning 
correlated with increased vascular maturation. Previous studies show increases in 
therapeutic efficacy when optimizing trastuzumab combination dosing regimens with 
cytotoxic therapy. This study offers preliminary evidence of immune mechanisms of 
vascular maturation and the potential for trastuzumab to reprogram an 
immunosuppressive tumor microenvironment, specifically by polarizing macrophages 
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towards an M1 phenotype. Further longitudinal assessments of trastuzumab induced 
immune changes may identify optimal combination regimens with immunotherapy and 
have potential to enhance clinical outcomes in breast cancer.   
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Chapter 5:  Quantifying the Effects of Combination Trastuzumab and 
Radiation Therapy in HER2+ Breast Cancer 
5.1 INTRODUCTION 
 Human epidermal growth factor receptor 2 (HER2) positive breast cancer is 
characterized by overexpression of the HER2/neu receptor and represents 15-20% of 
annual breast cancer cases [71]. Trastuzumab, a monoclonal antibody targeted to the 
HER2 receptor, is used clinically in both neoadjuvant and adjuvant standard-of-care 
treatment and is often combined with radiation in the adjuvant setting to eliminate 
residual disease and prevent recurrence [23, 163, 201]. Preclinical studies have shown 
that overexpression of HER2 is a contributing factor to radiation resistance, and treatment 
with anti-HER2 therapy could potentially act as a radiosensitizer [27–31]. However, 
HER2+ patients still have a greater chance of recurrence than patients with HER2- status 
[26]. Thus, there is a need to further investigate optimizing the use of trastuzumab and 
radiation in a combination treatment regimen.  
One mechanism by which HER2 overexpression promotes tumorigenesis is 
through inhibition of apoptosis by upregulation of the phosphatidylinositol 3'-kinase–
protein kinase B–mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. 
Trastuzumab blocks PI3K/AKT/mTOR pathway signaling, causing cell cycle arrest and 
inducing cancer cell death [202]. Studies from Guo et al. and Liang et al. found that 
combination trastuzumab sensitizes HER2+ breast cancer cells to radiation therapy in 
vitro, and that the upregulation of PI3K/AKT pathway may be specifically involved in 
radioresistance in HER2+ breast cancer [27, 29]. Additionally, breast tumors can become 
hypoxic due to the irregular and tortuous vasculature which increases radioresistance 
[203–205]. Breast cancer cells exposed to chronic hypoxia can develop lower levels of 
reactive oxygen species which prevents stabilization of DNA damage caused by radiation 
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and enhances cell survival [206, 207]. Godet et al. showed that breast cancer cells with 
lower reactive oxygen species levels due to chronic hypoxia exposure in vivo had a 
higher potential to invade surrounding tissue and were four times more likely to 
metastasize [207]. Previous results in HER2+ breast cancer have revealed that treatment 
with trastuzumab can increase tumor oxygenation in a pre-clinical mouse model through 
stabilization of tumor blood vessels [208]. Although there has been investigation into the 
potential radiosensitization ability of trastuzumab in breast cancer, studies lack 
longitudinal data and fail to quantify sensitization over time, reducing clinical relevance. 
Furthermore, the effects of the sequence of therapies has not been systematically 
investigated [209].  
 Common in vitro approaches for evaluating cell response to radiation therapy 
include end point analyses such as the 3-[4,5-dimethylthiazolyl-2]-2,5-
diphenyltetrazolium bromide (MTT) assay or the clonogenic assay. Results evaluating 
cell viability after treatment can largely vary depending on the end time point chosen 
[210]. However, these methods lack the ability to longitudinally observe cell response 
which is critical in determining underlying changes in cell physiology during therapy 
[211]. This study will use the IncuCyte Live-Cell Analysis System (Essen Bioscience, 
Ann Arbor, MI) which delivers real-time data of cellular responses and has been shown 
to be accurate in analyzing changes in breast cancer cell proliferation through time [212].  
This contribution has three goals 1) investigate the effects of radiation and 
trastuzumab in vitro, 2) quantify the effects of radiation and trastuzumab combination 
therapy longitudinally in vitro, and 3) test the hypothesis that trastuzumab sensitizes 
HER2+ breast cancer to radiation therapy in an in vivo model of HER2+ breast cancer. 
Quantifying the synergy between trastuzumab and radiation over time has the potential to 
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elucidate optimal combination regimens and decrease the amount of therapy needed to 
achieve rumor control or eradication.  
5.2 MATERIALS AND METHODS 
5.2.1 Cell Culture 
BT474 cells were maintained in improved minimal essential medium (IMEM, 
Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 1% penicillin/streptomycin, and 
20 μg/mL of insulin. SKBR3 cells were cultured in McCoy’s 5A medium (ATCC, 
Manassas, VA) supplemented with 10% FBS and 1% penicillin/streptomycin. MDA-MB-
231 cells were maintained in Dulbecco’s Modified Eagle’s Medium (Thermo Fisher 
Scientific Inc., Waltham, MA) supplemented with 5% FBS and 200 g/mL of G418. All 
cells were grown at 37 °C with 5% CO2. Cells were cultured to 70-80% confluency and 
cell counts were determined with the Countess II FL automated cell counter (Thermo 
Fisher Scientific Inc., Waltham, MA). 
5.2.2 Western Blot Evaluation of HER2 Expression and Quantification 
BT474, SKBR3 and MDA-MB-231 breast cancer cells were washed with ice cold 
phosphate buffered saline and lysed for 10 minutes on ice with radioimmunoprecipitation 
assay buffer (RIPA) buffer supplemented with protease inhibitor (Roche Applied 
Science, Indianapolis, IN). Lysates were centrifuged at 13,400 g for 20 minutes at 4° C 
and collected for bicinchoninic acid (BCA) protein quantification assay via the Nanodrop 
2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA). For each cell line, 
20 μg of protein was prepared in a solution of sodium dodecyl sulfate (SDS) and β-
mercaptoethanol and boiled for 5 minutes at 95° C. Samples were run on a NuPAGE Bis-
Tris gel and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane 
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was blocked in 5% dry milk in tris-buffered saline (TBST), probed with horseradish 
peroxidase (HRP) conjugated mouse anti-human β-actin overnight at 4° C and developed 
with the Amersham ECL western blot detection system (GE healthcare, 
Buckinghamshire, UK) for one minute at room temperature. Membranes were developed 
in the absence of light and visualized with an SRX-101A Medical Film Processor 
(Konica Minolta Medical and Garphic, Inc., Shanghai, China). The membrane was 
incubated in stripping buffer for 15 minutes, washed with TBST and probed with Rabbit 
anti-human HER2/ErbB2 primary antibody (Cell Signaling Technology, Danvers, MA) 
for 2 hours at room temperature. The membrane was washed, incubated with HRP 
conjugated goat anti-rabbit IgG secondary antibody (Cell Signaling Technology, 
Danvers, MA) for 1 hour at room temperature. After a final wash, the membrane was 
redeveloped and visualized for HER2 expression. Quantification of bands was conducted 
with the Image Studio Lite program, version 5.0 (LI-COR Biosciences, Lincoln, NE, 
USA). HER2 expression was normalized to β-actin expression for quantification.  
5.2.3 Transfection of Breast Cancer Cell Lines 
 Enhanced green fluorescent protein (EGFP) expressing BT474 and MDA-MB-
231 cells were a gift from Dr. Amy Brock at The University of Texas at Austin. SKBR3 
cells were transfected to express EGFP through a Sleeping Beauty Transposon System. 
An EGFP plasmid was obtained and cloned into a Sleeping Beauty compatible vector, 
psDBbi-Neo (Addgene, Cambridge, MA, plasmid #60525). Co-transfection of the 
psDBbi-Neo vector and the pCMV (CAT) T7-SB100 (Addgene, Cambridge, MA, 
plasmid #34879) Sleeping Beauty transposase was used to introduce the EGFP plasmid 
into the SKBR3 cell line through Lipofectamine LTX (Thermo Fisher Scientific, 
Waltham, MA). Following transfection, cells were cultured in their respective media 
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supplemented with 200 g/mL geneticin for four weeks to select for positively 
transfected cells. Fluorescence activated cell sorting was used to separate cells based on 
fluorescent expression, and the top 25% of EGFP expressing cells were used in 
experiments. The pCMV (CAT)T7-SB100 plasmid was a gift from Dr. Zsuzsanna Izsvak 
[213] and the pSBbie-Neo was a gift from Dr. Eric Kowarz [214].  
5.2.4 In Vitro Treatment Experiments 
5.2.4.1 Experiment 1: Order of dosing 
BT474-GFP cells were plated in 96-well plates at 5,000 cells/well. 24 hours later 
(Day 0), plates were placed in the IncuCyte S3 Live-Cell Analysis System (Essen 
BioScience, Ann Arbor, MI) and whole-well imaged every six hours with phase contrast 
and green channels (excitation 440-480, emission 504-544) for one week. Single agent 
trastuzumab treatment groups were treated with trastuzumab (0.1 ng/ml) from 0 to 48 
hours (group 1), 24-72 hours (group 2) or 48-96 hours (group 3). For single agent 
radiation treatment groups, cells were treated with radiation (10 Gy) at 24 hours with the 
CellRad Dedicated Benchtop Cell Irradiator (Faxitron, Tucson, AZ). For combination 
treatment groups, cells received trastuzumab (0.1 ng/ml) before, with, or after radiation 
treatment (10 Gy) as detailed in Figure 5.1a. Each treatment group has 24 wells of 
replicates. The experiment was performed three times.  
5.2.4.2 Experiment 2: Quantifying radiation + trastuzumab combination effects 
BT474-GFP, SKBR3-GFP or MDA-MB-231-GFP cells were plated in 96-well 
plates at 5,000 cells/well. 24 hours later (Day 0), cells were treated with either 0.1% 
saline, trastuzumab (0.1 ng/ml), or radiation (5 or 10 Gy) for control and single agent 
treatment groups. Combination groups received both trastuzumab (0.1 ng/ml) and 
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radiation (5 or 10 Gy) on Day 0 (Figure 5.1b). Plates were placed in the IncuCyte S3 
Live-Cell Analysis System (Essen BioScience, Ann Arbor, MI) and whole-well imaged 
every six hours with phase contrast and green channels (excitation 440-480, emission 
504-544) for one week. Each treatment group has 30 wells of replicates. Experiments 
were performed three times. 
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Figure 5.1: Treatment plans for in vitro experiments. a) Cells were treated with either 
trastuzumab (0.1 ng/ml) from 0-48 hours (1, before radiation), 24-72 hours 
(2, with radiation) or 48-96 hours (3, after radiation). All groups received 
radiation (10 Gy) at 24 hours. All groups were imaged every 6 hours for 
seven days. b) Cells were treated with trastuzumab (0.1 ng/ml) and radiation 
(5 or 10 Gy) at the start of the experiment (Day 0). Trastuzumab was 
removed 48 hours later. Cells were imaged every six hours for seven days.  
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5.2.5 Image Analysis 
 Images were analyzed using the IncuCyte S3 Live-Cell Analysis System (Essen 
BioScience, Ann Arbor, MI) to segment green fluorescent objects (cell counts). 
Background signal was estimated in 100 μm segments and subtracted from the image. 
Edgse of clumped cells were determined at the dimmest point between two objects. 
Objects greater than 1000 μm2 were filtered out of analysis. Cell growth was normalized 
to initial seeding density (0 hours). 
5.2.6 Bliss Interaction Index Calculation 
 The Bliss Interaction Index [215] was used to determine effects of combination 
radiation and trastuzumab treatment in vitro. To calculate the effects of radiation (A), 
trastuzumab (B) and combination treatment (AB) compared to the control (C), let (f) 
represent the difference in normalized cell growth (N):  
 
(1)        𝑓𝑖 =
𝑁𝐶− 𝑁𝑖
𝑁𝐶
   𝑖 = 𝐴, 𝐵, 𝐴𝐵 
 
The Bliss Interaction Index (I) can be calculated by Eq. (2): 
 
(2)           𝐼 = 𝑓𝐴𝐵 −  𝑓𝐴− 𝑓𝐵+ 𝑓𝐴𝑓𝐵  
 
and the value of I determines the effect of combination therapy:  
 
(3)          𝐼 = {
𝑆𝑦𝑛𝑒𝑟𝑔𝑖𝑠𝑡𝑖𝑐        𝐼 >  0
    𝐴𝑑𝑑𝑖𝑡𝑖𝑣𝑒          𝐼 =  0
𝐴𝑛𝑡𝑎𝑔𝑜𝑛𝑖𝑠𝑡𝑖𝑐     𝐼 <  0
       
 
5.2.7 Animal Procedures 
 All procedures were approved by our institution’s animal care and use committee. 
Female nude athymic mice (N = 46) were purchased from The Jackson Laboratory (Bar 
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Harbor, ME) at 3-4 weeks of age. Mice were then subcutaneously implanted with a 0.72 
mg, 60-day release, 17β-estradiol pellet (Innovative Research of America, Sarasota, FL) 
in the nape of the neck. One day later, 107 BT474 cells were implanted subcutaneously in 
100 μl of serum-free IMEM media with 30% growth factor-reduced Matrigel. Tumors 
were grown to approximately 250 mm3 (8-10 weeks) and entered into the study. Animals 
were randomly sorted into treatment groups:  1) Control: 100 μl saline on Days 0, 3 (N = 
6), 2) Trastuzumab alone: 10 mg/kg on Days 0, 3 (N = 7), 3) Radiation 5 Gy alone: Day 0 
(N = 6) + 100 μl saline on Day 3, 4) Radiation 10 Gy alone: Day 0 (N = 5) + 100 μl 
saline on Day 3, 5) Radiation 5 Gy on Day 0 + Trastuzumab 10 mg/kg on Days 0, 3 (N = 
5), 6) Radiation 10 Gy on Day 0 + Trastuzumab 10 mg/kg on Days 0, 3 (N = 5). 
Trastuzumab and saline were administered via intraperitoneal (IP) injection. Radiation 
treatments were given with the MultiRad 350 Irradiation System (Faxitron, Tucson, AZ). 
Tumor measurements were taken three times per week using calipers for four weeks at 
which point mice were euthanized. Mice in the immunohistochemistry cohort were 
divided into three treatment groups: 1) Radiation 5 Gy on Day 0 (N = 4) + 100 μl saline 
on Day 3, 2) Trastuzumab 10 mg/kg on Days 0, 3 (N = 4), 3) Radiation 5 Gy on Day 0 + 
Trastuzumab 10 mg/kg on Days 0, 3 (N = 4). Tumor growth was measured three times 
with calipers for one week at which point mice were euthanized and tumors were 
extracted. One hour prior to sacrifice, mice were intravenously injected with 60 mg/kg of 
pimonidazole (Hypoxyprobe, Inc., Burlington, MA) in 100 μl of saline. Tumors were cut 
at the longest cross-section and half was fixed in 10% neutral buffered formalin (Fisher 
Scientific International Inc., Pittsburgh, PA) for 48 hours where it was then placed in 
70% ethanol.  
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5.2.8 Immunohistochemistry  
 Formalin fixed tumor sections were embedded in paraffin and sliced into 4 μM 
sections. Sections were stained for hematoxylin and eosin (H&E), mouse anti-CD31, 
mouse anti-α-smooth muscle actin (α-SMA, Abcam, Cambridge, UK), mouse anti-CD45 
(Invitrogen, Carlsbad, CA) and anti-pimonidazole (Hypoxyprobe, Inc., Burlington, MA). 
Immuno-stained slides were scanned (20×, 0.495 μm/pixel) with the Aperio ScanScope 
(Leica Microsystems, Wetzlar, Germany). Regions of necrosis were determined using 
manual segmentation. All other stains were segmented based on thresholds determined 
from positive and negative controls using in house MATLAB (MathWorks Inc., Natick, 
MA) routines. Images were converted to grayscale for registration to the corresponding 
tumor H&E. Then, transformations consisting of translation, rotation and scale 
(similarity) based on intensity were applied.  A viable tissue mask was defined as total 
tumor area minus necrotic area. Inflammation (CD45), hypoxia (pimonidazole), and 
apoptosis (caspase3) were defined as the percent of positive stain per viable tissue area. 
Microvessel density (CD31) and vascular smooth muscle coverage (α-SMA) were 
calculated as the number of vessels per mm2 of tumor tissue. The vessel maturation index 
[40] was evaluated as the ratio of α-SMA coverage to microvessel density. All codes are 
available upon request. 
5.2.9 Statistical Analysis 
 Statistical analysis was conducted using MATLAB (MathWorks Inc., Natick, 
MA). A two-way analysis of variance (ANOVA), adjusting for multiple comparisons 
with Dunn’s, was used to determine longitudinal differences in order of dosing 
experiments. All in vitro data is presented as mean ± 95% confidence interval with P < 
0.05 indicating significance. Statistical differences between in vivo tumor growth at each 
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time point and ex vivo immunohistochemistry samples were determined using a 
nonparametric Wilcoxon rank sum test. All in vivo and ex vivo data is presented as mean 
± standard error with P < 0.05 indicating significance. The Friedman’s test adjusting for 
multiple comparisons with Dunn’s was used to assess longitudinal changes in tumor 
growth between treatment groups. 
5.3 RESULTS 
5.3.1 HER2 expression in BT474, SKBR3 and MDA-MB-231 cell lines 
 Quantification of HER2 protein expression in BT474, SKBR3, and MDA-MB-
231 cells confirmed reported HER2 status in each cell line (Figure 5.2). Western blot 
revealed visible bands of HER2 protein in BT474 and SKBR3 HER2+ cell lines at 185 
kDa, and showed little to no expression in MDA-MB-231 cells, a HER2- cell line (Figure 
5.2a). β-actin was used as an internal control for normalization of HER2 expression. 
Ratios of HER2:β-actin in BT474 and SKBR3 cells were 1.41 and 1.46, respectively, 
confirming HER2 overexpression. MDA-MB-231 cells had a HER2:β-actin ratio of 0.08, 
confirming no HER2 overexpression (Figure 5.2b).  
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Figure 5.2: HER2 quantification in BT474, SKBR3 and MDA-MB-231 cells. a) 
Expression of HER2 protein (185 kDa) in each cell line. β-actin (42 kDa) 
was used as an internal control. Visible protein bands are seen in the BT474 
and SKBR3 HER2+ cell lines while MDA-MB-231 shows little to no 
expression.  B) HER2:β-actin ratio in each cell line. BT474 and SKBR3 
cells have ratios of 1.41 and 1.46, respectively. MDA-MB-231 has a ratio of 
0.08, confirming no HER2 amplification.   
5.3.2 Order of radiation and trastuzumab therapy does not affect cell death 
response in vitro 
 Cells were administered single agent trastuzumab controls from 24-48 hours, 24-
72 hours and 48-96 hours. No significant differences were observed between these 
groups (Figure 5.3). In combination regimens, cells were treated with trastuzumab (0.1 
ng/ml) 24 hours before radiation (10 Gy) treatment, at the same time as radiation 
treatment, and 24 hours after radiation. No significant differences were seen in cell 
growth over time when comparing trastuzumab treatment before with treatment at the 
same time (P = 1.00) or treatment after (P = 0.98). Additionally, treatment with 
trastuzumab at the same time as radiation did not alter cell response over time compared 
to treatment after radiation (P = 0.93) (Figure 5.3). From these results, it was determined 
that order of dosing did not affect cell response to therapy and further experiments were 
conducted administering trastuzumab and radiation at the same time (Figure 5.1b).  
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Figure 5.3: Differences in BT474 cell growth with trastuzumab given before, at the same 
time, and after radiation therapy. Treatment with trastuzumab before 
radiation did not significantly alter cell response to therapy compared to 
treatment of trastuzumab at the same time (P = 1.00) or treatment after 
radiation (P = 0.98). Treatment with trastuzumab at the same time did not 
significantly alter cell response to therapy compared to treatment after 
radiation (P = 0.93). Altering the order of dosing of trastuzumab and 
radiation did not alter cell response to treatment in vitro.  
 
5.3.3 Quantification of longitudinal cell growth after combination therapy reveals 
additive effects in vitro 
 Figure 5.4 displays BT474, SKBR3 and MDA-MB-231 cell proliferation after 
being treated with trastuzumab (0.01 ng/ml), radiation (5 or 10 Gy), or combination 
treatment over one week.  No significant differences were observed through time in 
MDA-MB-231 cell proliferation between the control and trastuzumab single agent 
treatment groups (P = 0.88, panels e and f of Figure 5.4), which is to be expected in a 
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HER2- cell line not responsive with trastuzumab. There were also no significant 
differences in proliferation between the radiation single agent or combination treatment 
groups as expected (P = 0.84, Figure 5.4e and P = 0.80, Figure 5.4f). Eq. (2) was used to 
calculate the Bliss Interaction Index of combination treatment effects from radiation and 
trastuzumab. Figure 5.5 displays interaction index over time for each treatment group in 
Figure 5.4. No group had an interaction index that fell significantly above or below 0 at 




Figure 5.4: Cell proliferation over one week after radiation, trastuzumab or combination 
treatment. All trastuzumab single agent and combination groups were 
treated with 0.1 ng/ml of trastuzumab from 0-48 hours. All radiation single 
agent and combination groups were treated with 5 or 10 Gy radiation on 
Day 0. Graphs display proliferation of: a) BT474 cells after trastuzumab, 5 
Gy radiation and combination treatment, b) BT474 cells after trastuzumab, 
10 Gy radiation and combination treatment, c) SKBR3 cells after 
trastuzumab, 5 Gy radiation and combination treatment, d) SKBR3 cells 
after trastuzumab, 10 Gy radiation and combination treatment, e) MDA-
MB-231 cells after trastuzumab, 5 Gy radiation and combination treatment, 
f) MDA-MB-231 cells after trastuzumab, 10 Gy radiation and combination 
treatment. No significant difference was observed in control MDA-MB-231 
cell proliferation and cells treated with single agent trastuzumab (P = 0.88, e 
& f). No significant difference in cell proliferation was observed between 
cells treated with single agent radiation and cells treated with combination 
treatment (P = 0.84, e & P = 0.80, f).  
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Figure 5.5: Bliss interaction index calculated per time point over one week of treatment.  
All groups were treated with 0.01 ng/ml of trastuzumab. Graphs display 
interaction index of a) BT474 cells, 5 Gy radiation + trastuzumab, b) BT474 
cells, 10 Gy radiation + trastuzumab, c) SKBR3 cells, 5 Gy radiation + 
trastuzumab, d) SKBR3 cells, 10 Gy radiation + trastuzumab, e) MDA-MB-
231 cells, 5 Gy radiation + trastuzumab and f) MDA-MB-231 cells, 10 Gy 
radiation + trastuzumab. No group had an interaction index significantly 
above or below 0 at any time point, indicating additive treatment affects.  
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5.3.4 Tumor size decreases faster with combination therapy than either single 
therapy in vivo  
 Figure 5.6a displays tumor volume changes in response to trastuzumab, radiation 
and combination regimens over four weeks. Mice treated with 10 Gy radiation had a 
significantly greater decrease in tumor size than mice treated with 5 Gy radiation over 
time (P < 0.001). However, mice treated with trastuzumab + 5 Gy radiation revealed no 
statistical differences in tumor response over time compared to mice treated with 
trastuzumab + 10 Gy radiation (P = 0.56). Mice treated with trastuzumab + 5 Gy 
radiation had significantly smaller tumors than mice treated with trastuzumab alone on 
day 7 onwards (P < 0.05) with the exception of day 9 (P = 0.11) (Figure 5.6b). Mice 
treated with trastuzumab + 5 Gy radiation had significantly smaller tumors than mice 
treated with 5 Gy alone on day 2 onwards (P < 0.05) with the exception of day 25 (P = 
0.25) (Figure 5.6c). Mice treated with trastuzumab + 5 Gy radiation had significantly 





Figure 5.6: In vivo tumor growth response to single agent and combination trastuzumab 
and radiation therapy. All mice were treated with radiation on Day 0 and 
trastuzumab on Days 0 and 3. a) Displays all groups. There was a significant 
difference between groups treated with single agent 5 Gy and single agent 
10 Gy radiation (P < 0.001). There was no significant difference when 
adding trastuzumab to the regimen; Trastuzumab + Radiation (10 Gy) vs. 
Trastuzumab + Radiation (5 Gy) (P = 0.56). b) Displays trastuzumab single 
agent therapy compared to trastuzumab + 5 Gy radiation. Significant 
differences between tumor response are observed on days 7-28, excluding 
day 9. c) Displays single agent radiation therapy (5 Gy) compared to 
trastuzumab + 5 Gy radiation. Significant differences are observed in tumor 
response on days 2-28, excluding day 25. d) Displays single agent radiation 
(10 Gy) compared to trastuzumab + 5 Gy radiation. Significant differences 
are observed in tumor response on days 2-17.  
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5.3.5 Tumor immune infiltration was higher in mice that received trastuzumab 
treatment  
Figure 5.7a displays representative images of CD45+ staining in mice treated with 
radiation (5 Gy) on Day 0, trastuzumab (10 mg/kg) on Days 0 and 3, or combination 
radiation and trastuzumab. Mice treated with trastuzumab alone had significantly higher 
CD45+ staining (2.63 ± 0.73%) than mice treated with radiation alone (0.77 ± 0.13%) (P 
= 0.03) on Day 7. Mice treated with combination therapy also had significantly higher 
CD45+ staining (2.48 ± 0.44%) than mice treated with radiation alone (P = 0.03). No 
significant differences were observed between mice treated with trastuzumab alone and 
combination treatment (P = 1.00) (Figure 5.7b). No significant differences were observed 
between treatment groups (P > 0.05) in percent pimonidazole or vascular maturation 




Figure 5.7: Percent CD45+ in single agent radiation, trastuzumab and combination 
treated tumors on Day 7. All radiation single agent and combination groups 
were treated with 5 Gy of radiation on Day 0. All trastuzumab single agent 
and combination groups were treated with 10 mg/kg of trastuzumab on Days 
0 and 3. a) Representative images of CD45 staining in single agent and 
combination treatment groups. b) Percent CD45+ staining from central slice 
of tumors in single agent and combination treatment groups, revealing 
significant increases in CD45+ in trastuzumab single agent and trastuzumab 
+ radiation (5 Gy) compared to radiation alone (P = 0.03). No significant 
difference was seen in mice treated with single agent trastuzumab and 




Figure 5.8: Hypoxia and vascular staining in single agent radiation, trastuzumab and 
combination treated tumors. All radiation single agent and combination 
groups were treated with 5 Gy of radiation on Day 0. All trastuzumab single 
agent and combination groups were treated with 10 mg/kg of trastuzumab 
on Days 0 and 3.  a) Percent pimonidazole staining revealing no significant 
differences between treatment groups (P > 0.05). B) Vascular maturation 
index revealing no significant differences between treatment groups (P > 




 Trastuzumab and radiation are commonly used as adjuvant therapies in clinical 
treatment of HER2+ breast cancer. Radiation therapy can reduce recurrence rates in 
patients by eradicating remaining cancer cells after surgical removal of tumors, however, 
HER2+ patients have greater chances of recurrence than HER2- patients [24, 26, 127]. In 
vitro evidence suggests trastuzumab can sensitize HER2+ breast cancer cells to radiation 
through inhibition of signaling pathways involved in DNA repair mechanisms [27, 131], 
although, systematic evaluation of the order of therapies and longitudinal data of cell 
response are limited. This study demonstrates the order of therapy does not alter cell 
proliferation after treatment and longitudinal treatment effects are additive in vitro. In 
vivo, tumors regress faster when treated with combination therapy than either single agent 
therapy and there is evidence that immune modulation may impact treatment response.  
 The Bliss Interaction Index calculations (Figure 5.5) revealed additive effects 
from combination radiation and trastuzumab treatment across all cell types. This contrasts 
with others who have evaluated cell response to radiation and trastuzumab using end 
point assays [27, 31]. For example, Liang et al. found a synergistic effect from 
trastuzumab and radiation treatment with BT474 and SKBR3 cells 24 hours after therapy 
using an ELISA to evaluate apoptosis (cytoplasmic histone-associated DNA fragments) 
[27]. In their study, cells were pre-incubated with trastuzumab for 16 hours before 
radiation treatment; however, our results did not indicate pre-treatment with trastuzumab 
alters cell response to radiation (Figure 3). Rao et al. found a similar synergistic effect 
using SUM-149PT cells treated with a HER2 tyrosine-kinase inhibitor in combination 
with radiation therapy; though, this study used a longer pre-incubation time with 
trastuzumab (7 days) and evaluated cell growth two weeks after radiation treatment using 
a clonogenic assay [31]. Differences in results could arise from the alternate methods 
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used to detect cell response to treatment and differences in timing of evaluation after 
treatment. We believe our study accurately quantifies longitudinal cell growth after 
treatment and provides a better understanding of cellular dynamics after combination 
treatment than traditional end point assays.  
 In vivo tumor growth data shows significant differences in longitudinal tumor 
response between groups that were treated with 5 Gy and 10 Gy of radiation, however, no 
significant difference in longitudinal tumor response was observed between doses of 
radiation when trastuzumab was added to the treatment regimen (Figure 5.6a). This 
finding suggests a smaller dose of radiation could be used in combination with 
trastuzumab without decreasing efficacy. Additionally, results show a faster rate of tumor 
regression in groups treated with combination therapy compared to either single therapy 
(Figure 5.6b-d). 
To evaluate if microenvironmental alterations could be impacting treatment 
response, immune infiltration, hypoxia, and vascular maturation index were evaluated in 
tumors treated with 5 Gy radiation, trastuzumab and 5 Gy radiation in combination with 
trastuzumab seven days after treatment. CD45 histology staining revealed an increase in 
immune infiltration in treatment groups receiving trastuzumab (Figure 5.7b). Previously 
collected data revealed trastuzumab has the potential to reprogram the 
immunosuppressive components of the tumor microenvironment and could contribute to 
anti-tumor responses (Chapter 4). Evaluation of immune cell characterization and impact 
on tumor regression in this treatment regimen is needed to further elucidate mechanisms 
contributing to enhanced tumor regression in the combination treatment group. Although 
no significant differences were shown in hypoxia and vascular maturation index, previous 
studies using longitudinal imaging have revealed trastuzumab can reduce hypoxia and 
increase vascular perfusion [21, 208]. It is possible by employing longitudinal imaging 
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methods, windows of heightened oxygenation could be revealed and alternate order of 
dosing could enhance treatment response in vivo.  
 Limitations of this study include the lack of longitudinal data evaluating 
microenvironmental changes corresponding with tumor growth dynamics. As previously 
discussed in Chapter 4, immuno-PET imaging, is an alternative method that could 
longitudinally evaluate immune infiltration after treatment. 18F-Fluoromisonidazole 
positron emission tomography is one method used to monitor tumor oxygenation levels 
and dynamic contrast enhanced magnetic resonance imaging is an alternative method to 
quantitatively assess vascularity. Neither of these methods would allow for histological 
validation at every time point, however, they would offer finely time resolved data of 
tumor status over the course of treatment. This study used a single dose of radiation and 
provided preliminary data showing a lesser dose of radiation could be used in 
combination with trastuzumab to achieve the same therapeutic efficacy as a higher dose 
of radiation, however, additional studies should be conducted evaluating efficacy with a 
clinical treatment regimen which uses fractionated dosing. Additional trastuzumab 
treatment doses were investigated for the in vitro experiments in this study. Doses higher 
than 0.01 ng/ml exhibited greater decreases in cell proliferation in single agent treatment 
groups, however, did not affect combination treatment response. Doses lower than 0.01 
ng/ml had no significant effect on HER2+ cell growth, which is not biologically observed 
in vivo; therefore, 0.01 ng/ml was chosen as the appropriate treatment condition. It is 
possible using a higher seeding density would allow for evaluation of cell proliferation 
with a higher trastuzumab dose, although when cells become confluent, the IncuCyte 
system is less accurate in quantifying cell number [212].  
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5.5 CONCLUSION 
 This study demonstrates longitudinal assessment of growth dynamics can result in 
different conclusions than end point assays and differences in methodologies should be 
taken into consideration when evaluating cellular response to treatment. Furthermore, this 
study yielded preliminary data that using trastuzumab in combination with radiation has 
the potential to decrease the dose of radiation administered without affecting therapeutic 
efficacy. Histology data revealed treatment with trastuzumab increased immune 
infiltration compared to radiation alone. Further assessment of immune changes in single 
agent and combination regimens could identify mechanistic reasoning for differences in 
therapeutic efficacies.  
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Chapter 6:  Conclusion 
6.1 SUMMARY 
The goal of this dissertation was to characterize treatment-induced alterations of 
the tumor microenvironment for the use of guiding future combination regimens that 
will optimize treatment response in cancer.  Specifically, the aims of this work 
achieved an improved understanding of NF-κB signal dynamics and gene expression 
for investigating small molecule therapies inhibiting the NF-κB transcription factor 
(Chapter 3). Secondly, revealed a mechanistic understanding of anti-HER2 induced 
vascular changes and identified windows of reduced immune suppression in HER2+ 
breast cancer (Chapter 4). Lastly, quantified combination treatment effects of radiation 
and trastuzumab therapy in HER2+ breast cancer, revealing enhanced tumor regression 
using combination treatment in vivo. The results presented provide valuable insight of 
how the tumor microenvironment can dictate treatment response and the potential to 
modulate the tumor microenvironment to enhance therapeutic efficacy.  
6.2 FUTURE DIRECTIONS 
6.2.1 NF-κB Targeted Therapies 
The experimental data collected in Chapter 3 indicates that pathway analyses are 
needed to accurately assess the effects of targeted drugs. Further studies should be 
focused in high throughput analyses of gene expression patterns. Analyzing which genes 
are activated early vs. late would increase understanding of inflammatory processes in 
cancer. Additionally, the gene expression patterns could identify genes that have steady 
state expression patterns vs. fluctuating expression patterns; furthering understanding of 
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cellular decision making in disease. This dataset is currently deposited on the NIH 
Sequence Read Archive.  
6.2.2 Immune Response in HER2+ Breast Cancer 
Chapter 4 evaluated innate immune alterations after treatment with trastuzumab. 
Further studies should evaluate immune infiltration after trastuzumab treatment in a 
mouse with a full immune system including T-cells. This would be valuable to determine 
any differences in trastuzumab vascular remodeling as well as conducting studies to 
guide immunotherapy treatment regimens. This work will be continued under the 
direction of Dr. Anna Sorace at the University of Alabama – Birmingham. Additionally, 
further systematic evaluation of cytokines contributing to the reprogramming of 
macrophages towards an M1 phenotype would be beneficial in identifying potential small 
molecule therapies that could be used in cancer to reprogram immunosuppressive innate 
immune components of the tumor microenvironment.  
6.2.3 Radiation and Trastuzumab Combination Treatment 
The results detailed in Chapter 5 revealed the potential of trastuzumab to increase 
the efficacy of radiation therapy in a combination regimen. Further studies should 
investigate this phenomenon using a dosing regimen similar to that in the clinic 
(fractionated radiation), as well as if order of trastuzumab and radiation effect treatment 
response in vivo. Furthermore, longitudinal analysis of vascular and immune alterations 
coinciding with therapeutic dosing could identify mechanisms of enhanced tumor 
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